<SEC-DOCUMENT>0001601830-24-000093.txt : 20240627
<SEC-HEADER>0001601830-24-000093.hdr.sgml : 20240627
<ACCEPTANCE-DATETIME>20240627130408
ACCESSION NUMBER:		0001601830-24-000093
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20240627
DATE AS OF CHANGE:		20240627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RECURSION PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001601830
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464099738
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-264845
		FILM NUMBER:		241077676

	BUSINESS ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101
		BUSINESS PHONE:		(385) 269-0203

	MAIL ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Recursion Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20140305
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>rxrxfinalprospectussupplem.htm
<DESCRIPTION>424B5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0890d7c4463a4953bcd09119a35873e9_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Pursuant to Rule 424(b)(5)<br>Registration No. 333-264845</font></div><div><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(to Prospectus dated May 10, 2022)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">30,769,230 Shares</font></div><div style="text-align:center"><img alt="recursionlogohorizontalbla.jpg" src="recursionlogohorizontalbla.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:261px"></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Class A Common Stock</font></div><div style="margin-top:12pt;padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are offering 30,769,230 shares of our Class A common stock, $0.00001 par value per share, or Class A Common Stock, in this offering.</font></div><div style="margin-top:12pt;padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol &#8220;RXRX.&#8221; On June 26, 2024, the last reported sale price of our Class A Common Stock, as reported on the Nasdaq Global Select Market, was $8.76 per share.</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.928%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing in our Class A Common Stock involves significant risks. Please carefully read the information under the headings &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125563" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221; beginning on page S-7 of this prospectus supplement and the information included and incorporated by reference in this prospectus supplement and the accompanying prospectus before investing in our Class A Common Stock. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement and the accompanying prospectus. Any representation to the contrary is a criminal offense.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.369%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per&#160;Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public offering price</font></div></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.50000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$199,999,995</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underwriting discounts and commissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.36075</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11,100,000</font></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds, before expenses, to Recursion Pharmaceuticals, Inc.</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.13925</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$188,899,995</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See &#8220;Underwriting&#8221; for a description of the compensation payable to the underwriters.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters have the option to purchase up to an additional 4,615,384 shares of our Class A Common Stock from us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters expect to deliver the shares against payment in New York on or about June 28, 2024.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.789%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Goldman Sachs&#160;&#38; Co. LLC</font></td><td colspan="12" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-8.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">J.P. Morgan </font></div></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Allen &#38; Company LLC</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.864%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospectus supplement dated June 26, 2024 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_4"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prospectus Supplement </font></div><div style="padding-left:1.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0890d7c4463a4953bcd09119a35873e9_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">About This Prospectus Supplement</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-i</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0890d7c4463a4953bcd09119a35873e9_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Supplement Summary</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i9763717ebfd546cdb50199387c82fad6_10656" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The Offering</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125563" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125564" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125565" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-12</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.1pt;text-indent:-10.1pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125566" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dilution</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125558" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Policy</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125559" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Capital Sto</a></font><font style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ck</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-16</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125560" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Material U.S. Federal Income Tax Considerations for Non-U.S. Holders of Our Common Stock</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125561" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Underwriting</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-27</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125567" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Matters</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-39</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125568" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Experts</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-39</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125569" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-39</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5787c211d1b749ea8a0ca88dd26b0683_125562" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Information Incorporated by Reference</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-40</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prospectus</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:91.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.237%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_1" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">About this Prospectus</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_2" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Summary</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_3" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_4" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Forward-Looking&#160;Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_5" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_6" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Capital Stock</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Debt Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_8" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Depositary Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_9" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Warrants</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_10" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Subscription Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_11" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Purchase Contracts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_12" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Units</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_13" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan of Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_14" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_15" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Experts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_16" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_17" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation by Reference</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_7"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i3a44bebd357245b295261fd2b77eddeb_6002"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS SUPPLEMENT </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document is part of the registration statement on Form S-3 (File No. 333-264845) that we filed on May 10, 2022 with the Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering and also supplements and updates information contained in the accompanying prospectus. The second part is the accompanying prospectus, including the documents incorporated by reference, which provides more general information, some of which may not apply to this offering.  Generally, when we refer to the &#8220;prospectus,&#8221; we are referring to both parts combined. This prospectus supplement may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference into each include important information about us, the securities being offered and other information you should know before investing in our Class A Common Stock. You should also read and consider information in the documents we have referred you to in the sections of this prospectus supplement and the accompanying prospectus entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Information Incorporated by Reference.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to the registration statement or any document that is incorporated by reference herein or into the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized, and the underwriters have not authorized, anyone to provide you with any information or to make any representations other than those contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we may have authorized for use in connection with this offering. Neither we nor the underwriters take any responsibility for, and can provide no assurances as to the reliability of, any information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We are not offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus that we may have authorized for use in connection with this offering is accurate as of any date other than as of the date of this prospectus supplement, the accompanying prospectus or such free writing prospectus, as the case may be, or in the case of the documents incorporated by reference, the date of such documents, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus and any free writing prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this prospectus supplement to &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively, to Recursion Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries, unless we state otherwise or the context otherwise requires. We use the Recursion Pharmaceuticals logo, and other marks as trademarks in the United States and other countries. This prospectus supplement, the accompanying prospectus and any free writing prospectus that we may have authorized for use in connection with this offering and the information incorporated herein or therein, as the case may be, by reference contain references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus supplement, the accompanying prospectus and any free writing prospectus that we may have authorized for use in connection with this offering, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-i</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No action is being taken in any jurisdiction outside the United States to permit a public offering of the securities or possession or distribution of this prospectus supplement or the accompanying prospectus in that jurisdiction. Persons who come into possession of this prospectus supplement or the accompanying prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus supplement or the accompanying prospectus applicable to that jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-ii</font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_10"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="padding-left:1pt;padding-right:1pt;text-align:center"><font id="i9763717ebfd546cdb50199387c82fad6_10655"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT SUMMARY </font></div><div style="margin-top:12pt;padding-left:1pt;padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights selected information that is incorporated by reference in this prospectus supplement, the accompanying prospectus and any related free writing prospectus. It does not contain all of the information that may be important to you and your investment decision. Before investing in our Class A Common Stock, you should carefully read this entire prospectus supplement, the accompanying prospectus, including the matters set forth under the sections &#8220;Risk Factors&#8221; of this prospectus supplement, the accompanying prospectus and any related free writing prospectus, as well as the financial statements and related notes and other information that we incorporate by reference herein and therein, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q and the exhibits to the registration statement of which this prospectus supplement and the accompanying prospectus is a part. Unless the context otherwise requires, the terms &#8220;Recursion,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus supplement and the accompanying prospectus refer to the operations of Recursion Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries as a whole. </font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview </font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to our mission is the Recursion Operating System, or OS, a platform built across diverse technologies that enables us to map and navigate trillions of biological</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> chemical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patient-centric </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationships </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">across over 50 petabytes</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of proprietary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data.</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We frame this integration of the physical and digital components as iterative loops</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where scaled</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;wet-lab&#8221; biology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> chemistry </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patient-centric experimental data</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are organized </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;dry-lab&#8221; computational tools </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identify, validate and </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">translate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> insights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe Recursion&#8217;s unbiased, data-driven approach to understanding</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> biology </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will bring more, new and better medicines at higher scale and lower cost</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three key value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at Recursion</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt;text-indent:35pt"><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. An expansive </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">pipeline</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of internally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed clinical and preclinical programs focused on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precision oncology and </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genetically</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">driven rare diseases with significant unmet need and market opportunities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that could</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potentially </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceed</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1 billion in annual sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in some cases&#59;</font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt;text-indent:35pt"><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Transformational </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">partnerships</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with leading biopharmaceutical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and technology</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companies to map and navigate intractable areas of biology, identify novel targets and develop potential new medicines </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by using advanced computational and data resources&#59; and</font></div><div style="margin-top:18pt;padding-left:1pt;padding-right:1pt;text-indent:35pt"><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. An industry-leading </font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">dataset</font><font style="background-color:#ffffff;color:#1e1e1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intentionally designed to capitalize on computational tools and accelerate value created through our pipeline, partnerships and technology capabilities.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:314px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We drive value by scaling and leveraging the Recursion OS to generate, aggregate and integrate over 50 petabytes of data spanning large language model derived disease relevance and target-compound relationships, predicted protein-ligand binding interactions for &#126;36 billion compounds, over 250 million total staining and multi-timepoint live-cell (brightfield) phenomics experiments, over 1 million whole transcriptomics experiments, tens of thousands of absorption, distribution, metabolism and excretion, or ADME, experiments using our automated drug metabolism and pharmacokinetics (DMPK) module, InVivomics and multimodal precision oncology patient data. This dataset has been curated using over 50 human cell types, our cell manufacturing facility which has produced over 1 trillion human induced pluripotent stem cell (hiPSC) derived neuronal cells since 2022, our in-house chemical library of over 1.7 million compounds, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">in silico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> library of over 1 trillion small molecules and other capabilities. We have built proprietary software applications and AI&#47;ML models within the Recursion OS that predict and navigate over 6 trillion biological and chemical relationships. With our approach and our team of over 500 Recursionauts that is balanced between life scientists and computational and technical experts, we endeavor to turn drug discovery into a search problem, where we map and navigate biology in an unbiased manner in order to translate insights into more, new and better medicines at higher scale and lower cost to patients.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="text-align:center"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:355px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-right:1pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Updated pipeline guidance</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:1pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seven clinical trial readouts expected within approximately 18 months&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">REC-994 Cerebral Cavernous Malformation&#8212;topline Phase 2 data readout in September 2024&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">REC-2282 Neurofibromatosis Type 2&#8212;preliminary Phase 2 data readout in the fourth quarter of 2024&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">REC-4881 Familial Adenomatous Polyposis&#8212;preliminary Phase 2 data readout in the first half of 2025&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">REC-4881 Advanced AXIN1&#47;APC-Mutant Cancers&#8212;preliminary Phase 2 data readout in the first half of 2025&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">REC-3964 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Infection&#8212;Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">RBM39 Advanced HR-Proficient Cancers&#8212;IND submission in the third quarter of 2024, Phase 1&#47;2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Epsilon (Fibrotic Diseases)&#8212;IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline.</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font><br></font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnership updates</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory, and intuitive research environment for scientists on both sides.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Additional updates pertaining to the Bayer partnership include&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We initiated our first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We are on track to complete 25 unique multi-modal data packages that we expect to deliver in the third quarter of 2024.</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform updates</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ADME industrialization&#58; potential to achieve an estimated 90 times the amount of lab throughput over a manual approach.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Built our first genome-scale transcriptomics knockout map.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multimodal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mapping has enabled us in certain experiments to achieve 90% success on our ability to predict compounds that failed later disease-relevant assays in internal tests and 60% ability to predict compounds that passed later disease-relevant assays in internal tests.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Helix partnership brings hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.</font></div><div style="padding-right:1pt;text-align:justify"><font><br></font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and History</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font><br></font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and subsequently changed our name to Recursion Pharmaceuticals, Inc. Our principal executive office is located at 41 S Rio Grande Street, Salt Lake City, Utah 84101. Our telephone number is (385) 269-0203. Our website is www.recursion.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus supplement or the accompanying prospectus and is not incorporated by reference herein or therein. We have included our website address in this prospectus supplement solely for informational purposes and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus supplement or in deciding whether to purchase shares of our Class A Common Stock, except as set forth under the section entitled &#8220;Information Incorporated by Reference.&#8221;</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:center"><font><br></font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="margin-bottom:6pt;padding-left:1pt;padding-right:1pt;text-align:center"><font id="i9763717ebfd546cdb50199387c82fad6_10656"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE OFFERING </font></div><div style="padding-left:1.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:37.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Common Stock offered by us </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,769,230 shares of our Class A Common Stock.  We have also granted the underwriters an option for a period of 30 days to purchase up to an additional 4,615,384 shares of our Class A Common Stock.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Common Stock to be outstanding following the offering</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,812,291 shares of our Class A Common Stock (or 265,427,675 shares of our Class A Common Stock if the underwriters&#8217; option to purchase additional shares of our Class A Common Stock is exercised in full) outstanding as of March 31, 2024 and which excludes certain shares as further described below.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock, $0.00001 par value per share, or Class B Common Stock, to be outstanding following the offering </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,464,871 shares of our Class B Common Stock.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of proceeds </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the net proceeds from this offering will be approximately $188.0 million, or approximately $216.4 million if the underwriters exercise their option to purchase additional shares of Class A Common Stock in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds of this offering to fund advancement of our existing preclinical and clinical programs and platform technologies, foundation model construction, industrialized validation and translation and scientific and technical personnel, as well as runway extension, strategic investments and acquisitions and general corporate purposes. However, we have no current agreements, commitments or understandings for any specific acquisitions or strategic investments at this time. See the section titled &#8220;Use of Proceeds&#8221; for more information.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voting rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our Class A Common Stock are entitled to one vote per share.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our Class B Common Stock are entitled to 10 votes per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our Class A Common Stock and Class B Common Stock generally vote together as a single class, unless otherwise required by law or our amended and restated certificate of incorporation. Upon completion of this offering, Dr. Gibson and his affiliates, will hold outstanding shares of our Class B Common Stock representing approximately 23% of the voting power of our outstanding capital stock in the aggregate, which voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all such equity awards held by Dr. Gibson had been fully vested and exercised and exchanged for shares of Class B Common Stock as of the date of completion of this offering, Dr. Gibson and his affiliates would hold approximately 24% of the voting power of our outstanding capital stock as of such date. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of our stockholders. See the section titled &#8220;Description of Capital Stock&#8221; for additional information.</font></div></td></tr></table></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:48.00pt 48.00pt 48.00pt 48.00pt"><div style="padding-left:1.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:37.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Global Select Market symbol </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;RXRX&#8221; </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing in our Class A Common Stock involves risks. See &#8220;Risk Factors&#8221; beginning on page S-7 of this prospectus supplement and other information included or incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the factors you should carefully consider before deciding to invest in our securities.</font></td></tr></table></div><div style="padding-left:1pt;padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of our Class A Common Stock and Class B Common Stock to be outstanding after the offering is based on 230,043,061 shares of Class A Common Stock and 7,464,871 shares of Class B Common Stock outstanding as of March 31, 2024, and excludes&#58;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,182,636 shares of Class A Common Stock issuable upon the exchange, retraction or redemption of exchangeable shares of a subsidiary of our company as of March 31, 2024&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">16,033,232 shares of Class A Common Stock issuable upon the exercise of stock options outstanding as of March 31, 2024, at a weighted average exercise price of $6.99 per share&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">15,631,543 shares of Class A Common Stock issuable upon the vesting of restricted stock units outstanding as of March 31, 2024&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up to an aggregate of $161.6 million of shares of Class A Common Stock that may be sold under our &#8220;at-the-market&#8221; program with Jefferies LLC&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">5,023,963 shares of Class A Common Stock sold through our &#8220;at-the-market&#8221; program with Jefferies LLC after March 31, 2024&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">18,939,412 shares of Class A Common Stock reserved for future issuance under our 2021 Equity Incentive Plan, or our 2021 Plan, as of March 31, 2024, plus any future increases in the number of shares of Class A Common Stock reserved for issuance under our 2021 Plan pursuant to the evergreen provision of our 2021 Plan&#59; </font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">7,997,240 shares of Class A Common Stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or our 2021 ESPP, as of March 31, 2024, plus any future increases in the number of shares of Class A Common Stock reserved for issuance under our 2021 ESPP pursuant to the evergreen provision of our 2021 ESPP&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares of Class A Common Stock that may become payable pursuant to the terms of the additional consideration arrangements in connection with our acquisition of Cyclica, Inc., or Cyclica, including 172,497 shares of Class A common stock of additional consideration that had not yet been issued as of March 31, 2024&#59;</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">220,557 shares of Class A Common Stock and 600,703 shares of a subsidiary of our company exchangeable for shares of Class A Common Stock that were issued pursuant to the release of shares withheld for potential indemnification claims in connection with our acquisition of Valence Discovery Inc., or Valence, after March 31, 2024&#59; and</font></div><div style="margin-top:6pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any shares of Class A Common Stock that we elect to issue in order to make annual payments in equity in connection with our collaboration agreement with Tempus Labs, Inc., or Tempus.</font></div><div style="margin-top:6pt;padding-right:0.7pt;text-align:justify;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, all information in this prospectus supplement assumes&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no exercise by the underwriters of their option to purchase up to 4,615,384 additional shares of Class A Common Stock in this offering&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no exercise or settlement of stock options, RSUs or other equity awards described above, no grant of additional awards under our 2021 Plan, and no issuance of shares under our 2021 ESPP, in each case, after March 31, 2024.</font></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_13"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125563"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our Class A Common Stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks referenced below and those described under Part I, Item 1A, Risk Factors and elsewhere in our Annual Report on Form 10-K for the period ended December 31, 2023, under Part II, Item 1A, Risk Factors and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, our Current Reports on Form 8-K and other documents we subsequently file with the SEC that are deemed incorporated by reference into this prospectus supplement. Our business, financial condition, results of operations and prospects could be materially adversely affected by the materialization of any of these risks. The trading price of our Class A Common Stock could decline due to the realization of any of these risks, and you may lose all or part of your investment. This prospectus supplement and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks referenced below and described in the documents incorporated herein by reference. Please also read carefully the section below titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Class A Common Stock and this Offering</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our Class A Common Stock may be volatile and you could lose all or part of your investment.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Class A Common Stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, investors may not be able to sell their common stock at or above the purchase price. The market price for our Class A Common Stock may be influenced by many factors, including the other risks described in this section and the following&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies and clinical trials of our drug candidates or those of our competitors or our existing or future collaborators&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries, including actions taken by regulatory agencies with respect to our drug candidates, clinical trials, manufacturing process or sales and marketing terms&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our drug candidates or clinical development programs and our ability or inability to raise additional capital and the terms on which any additional capital is raised&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire, or in-license additional drug candidates or drug products&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet expectations of research analysts or unfavorable research reports released by research analysts&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the concentrated ownership of our common stock&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inflation, general supply chain matters, global political instability, or warfare&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of the overall stock market and shares of biotechnology companies in particular, as well as general economic conditions, including fluctuating interest rates, inflation and the possibility of a recession or other economic downturn.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of volatility in the price of our Class A Common Stock, holders of our Class A Common Stock may not be able to sell their stock at or above the price they originally paid for it, which could result in the loss of a part or all of their investment.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will have broad discretion in how we use the net proceeds of this offering. We may not use these proceeds effectively, which could affect our business, financial condition, results of operations and prospects and cause the price of our Class A Common Stock to decline.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently intend to use the net proceeds from this offering in the manner described in the section entitled &#8220;Use of Proceeds&#8221; in this prospectus supplement, we will have considerable discretion in the application of the net proceeds of this offering. You will not have the opportunity, as part of your investment decision, to assess whether we are using the proceeds appropriately. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of our Class A Common Stock to decline.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you purchase shares of Class A Common Stock sold in this offering, you will incur immediate and substantial dilution. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will suffer immediate and substantial dilution in the net tangible book value of our Class A Common Stock that you purchase in this offering. At the public offering price of $6.50 per share, purchasers of Class A Common Stock in this offering will experience immediate dilution of $4.69 per share in net tangible book value of our Class A Common Stock. This dilution is due to the fact that the price per share at which shares of our Class A Common Stock are sold in this offering may be substantially higher than the net tangible book value per share of our Class A Common Stock. You will experience additional dilution upon exercise of the outstanding stock options and other equity awards that may be granted under our equity incentive plans, and when we otherwise issue additional shares of our common stock. For a further description of the dilution that you will experience immediately after this offering, see the section in this prospectus supplement entitled &#8220;Dilution.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resales of our Class A Common Stock in the public market by our stockholders as a result of this offering may cause the market price of our Class A Common Stock to fall.  In addition, a significant number of our total outstanding shares of Class A Common Stock may be sold into the market in the near future, which could cause the market price of our Class A Common Stock to drop significantly.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our Class A Common Stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our Class A Common Stock. The issuance of new shares of our Class A Common Stock in this offering could result in resales of our Class A Common Stock by our current stockholders concerned about the potential ownership dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our Class A Common Stock.</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 and July 2023, we completed private placements of shares of our Class A Common Stock to several accredited investors. We have filed registration statements covering the resale of these shares by the purchasers in these private placements and have agreed to keep such registration statements effective until the date the shares covered by the respective registration statement have been sold or can be resold without restriction under Rule 144 of the Securities Act of 1933, as amended, or the Securities Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125564"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">This prospectus supplement and the information incorporated by reference in this prospectus supplement contain statements, estimates and projections that are &#8220;forward-looking statements&#8221; as defined under U.S. federal securities laws and within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our beliefs, projections and predictions about future events or our future performance, and speak only as of the date we make them. You can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative or plural of these terms or other similar expressions or phrases, including references to assumptions. Although we believe that our plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, we cannot assure you that such plans, intentions or expectations will be achieved. By their nature, forward-looking statements involve risks, uncertainties, and other factors beyond our control that could cause our actual results to differ materially from our historical experience or from our current expectations or projections. Risks and factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, Risk Factors and elsewhere in our Annual Report on Form 10-K for the period ended December 31, 2023, under Part II, Item 1A, Risk Factors and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended&#160;March&#160;31, 2024, our Current Reports on Form 8-K, and the sections of this prospectus supplement and the accompanying prospectus entitled &#8220;Risk Factors.&#8221; In addition to these risks and uncertainties, important factors that could cause actual results to differ materially from our forward-looking statements include, but are not limited to&#58;</font></div><div style="text-align:justify;text-indent:20pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our current and future preclinical studies and clinical trials, including statements regarding the design of, and the timing of initiation and completion of, studies and trials and related preparatory work, as well as the period during which the results of the studies and trials will become available&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate the safety and efficacy of our drug candidates, and other positive results&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development programs&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope, or likelihood of regulatory filings and approvals, including the timing of Investigational New Drug applications and final approval by the U.S. Food and Drug Administration of our current drug candidates and any other future drug candidates, as well as our ability to maintain any such approvals&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope, or likelihood of foreign regulatory filings and approvals, including our ability to maintain any such approvals&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our collaborators to continue research and development activities relating to our development candidates and investigational medicines&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines and any other approved product&#59;  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the potential market opportunity for our drug candidates, including our estimates of the number of patients who suffer from the diseases we are targeting and potential annual sales&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify viable new drug candidates for clinical development and the rate at which we expect to identify such candidates, whether through an inferential approach or otherwise&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that the assets that will drive the most value for us are those that we will identify in the future using our datasets and tools&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance our current drug candidates and programs into, and successfully complete, clinical studies&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reduce the time or cost or increase the likelihood of success of our research and development relative to the traditional drug discovery paradigm&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to improve, and the rate of improvement in, our infrastructure, datasets, biology, technology tools and drug discovery platform, and our ability to realize benefits from such improvements&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations related to the performance and benefits of our BioHive supercomputer, including our ongoing and planned expansion of the BioHive supercomputer capabilities&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize a return on our investment of resources and cash in our drug discovery collaborations&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate acquired businesses with our existing programs and platform and realize a return on acquired assets&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to leverage datasets acquired through licenses with third parties, including with Tempus, into increased machine learning capabilities, novel genetic associations and mechanisms, innovative therapeutics, or other beneficial outcomes&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to derive value from our Recursion OS by licensing subsets of data and key tools&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to construct and apply more and increasingly sophisticated foundation models and large language models across biology, chemistry and translation and to use these models to drive new, better programs into clinical development both in our own pipeline and with our current and future partners at scale&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to scale like a technology company, including scaling our Recursion OS, and to add more programs to our pipeline each year&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully compete in a highly competitive market, including our competitive position and the success of competing approaches that are or may become available&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization and marketing capabilities and strategies&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our drug candidates, if approved, including the geographic areas of focus and sales strategy&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the approval and use of our drug candidates in combination with other drugs&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current drug candidates, if approved, and other drug candidates we may develop&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our drug candidates&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans for further development of our drug candidates, including additional indications we may pursue&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately protect and enforce our intellectual property and proprietary technology, including the scope of protection we are able to establish and maintain for intellectual property rights covering our current drug candidates and other drug candidates we may develop, receipt of patent protection, the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, the protection of our trade secrets, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any intellectual property disputes and our ability to defend against claims of infringement, misappropriation, or other violations of intellectual property rights&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to keep pace with new technological developments&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize third-party open source software and cloud-based infrastructure, on which we are dependent&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of our insurance policies and the scope of their coverage&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of a pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, or natural disaster, global political instability or warfare, and the effect of such outbreak or natural disaster, global political instability or warfare on our business and financial results&#59;  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our technical operations infrastructure to avoid errors, delays, or cybersecurity breaches&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and negotiate favorable terms of, any collaboration, licensing, or other arrangements that may be necessary or desirable to research, develop, manufacture, or commercialize our platform and drug candidates&#59;  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our current drug candidates and other drug candidates we may develop, if approved&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and need for additional financing&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise substantial additional funding&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of current and future laws and regulations, and our ability to comply with all regulations that we are, or may become, subject to&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any current or future litigation, which may arise during the ordinary course of business and be costly to defend&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to raise additional capital may cause dilution to our stockholders, restrict our operations, require us to relinquish rights to our technologies or drug candidates, and divert management&#8217;s attention from our core business&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the net proceeds from this offering&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein or therein reflect our current views with respect to future events and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. All forward-looking statements, expressed or implied, included in this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein are expressly qualified in their entirety by the statements in this cautionary note. This cautionary note should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein also contain estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information provided. Unless otherwise expressly stated, we obtained this industry information, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in each case, from sources we consider to be reliable, and in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125565"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS </font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We estimate that the net proceeds from this offering will be approximately $188.0 million, or approximately $216.4 million if the underwriters exercise in full their option to purchase additional shares of Class A Common Stock, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We intend to use the net proceeds of this offering to fund advancement of our existing preclinical and clinical programs and platform technologies, foundation model construction, industrialized validation and translation and scientific and technical personnel, as well as runway extension, strategic investments and acquisitions and general corporate purposes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. We cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above and we may require additional funds in order to fully accomplish the specified uses listed above. We believe opportunities may exist from time to time to expand our current business through in-licenses or acquisitions of, or investments in, complementary businesses, products or technologies. While we have no current agreements, commitments or understandings for any specific acquisitions or strategic investments at this time, we may use a portion of the net proceeds for these purposes, subject to applicable regulatory restrictions. As a result, our management will have broad discretion over the use of the net proceeds from this offering.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The amounts and timing of our actual expenditures and the extent of drug candidate development may vary significantly depending on numerous factors, including the progress of our research and development, formulation and manufacturing matters, the timing and success of our current preclinical studies and clinical trials and those we may commence in the future, the timing of patient enrollment in clinical trials, the timing of regulatory submissions and evolving regulatory requirements, any collaboration arrangements that we may enter into with third parties or strategic opportunities that become available to us, and any unforeseen cash needs.</font></div><div style="text-align:justify;text-indent:20pt"><font><br></font></div><div style="text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pending their use, we intend to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government, subject to applicable regulatory restrictions. We cannot predict whether the proceeds invested will yield a favorable return.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125566"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DILUTION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you invest in our Class A Common Stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our Class A Common Stock and the as adjusted net tangible book value per share of our Class A Common Stock immediately after this offering.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical net tangible book value as of March 31, 2024 was $284.3 million, or $1.24 per share of our Class A Common Stock. Our historical net tangible book value is the amount of our total tangible assets less our total liabilities. Historical net tangible book value per share represents historical net tangible book value divided by the number of shares of our Class A Common Stock outstanding as of March 31, 2024.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After giving further effect to the sale of&#160;30,769,230 shares of Class A Common Stock in this offering at the public offering price of&#160;$6.50 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2024 would have been approximately&#160;$472.4&#160;million, or approximately&#160;$1.81&#160;per share. This represents an immediate increase in as adjusted net tangible book value per share of&#160;$0.57 to our existing stockholders and an immediate dilution in as adjusted net tangible book value per share of approximately&#160;$4.69&#160;to new investors purchasing Class A Common Stock in this offering. Dilution in net tangible book value per share to new investors purchasing Class A Common Stock in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates this per share dilution&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public offering price per share</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.50</font></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical net tangible book value per share as of March 31, 2024</font></div></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.35pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in net tangible book value per share attributable to new investors</font></div></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.57</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As adjusted net tangible book value per share after this offering</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.81</font></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilution per share to new investors</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.69</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the underwriters exercise in full their option to purchase up to 4,615,384 additional shares of Class A Common Stock at the public offering price of $6.50 per share, the as adjusted net tangible book value after this offering would be $1.89&#160;per share, representing an increase in net tangible book value of $0.65 per share to existing stockholders and immediate dilution in net tangible book value of $4.61 per share to investors purchasing our Class A Common Stock in this offering at the public offering price.</font></div><div style="padding-left:1pt;padding-right:1pt;text-align:justify;text-indent:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing table and discussion is based on 230,043,061 shares of Class A Common Stock and 7,464,871 shares of Class B Common Stock outstanding as of March 31, 2024, and excludes&#58;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,182,636 shares of Class A Common Stock issuable upon the exchange, retraction or redemption of exchangeable shares of a subsidiary of our company as of March 31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">16,033,232 shares of Class A Common Stock issuable upon the exercise of stock options outstanding as of March 31, 2024, at a weighted average exercise price of $6.99 per share&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">15,631,543 shares of Class A Common Stock issuable upon the vesting of restricted stock units outstanding as of March 31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up to an aggregate of $161.6 million of shares of Class A Common Stock that may be sold under our &#8220;at-the-market&#8221; program with Jefferies LLC&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">5,023,963 shares of Class A Common Stock sold through our &#8220;at-the-market&#8221; program with Jefferies LLC after March 31, 2024&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">18,939,412 shares of Class A Common Stock reserved for future issuance under our 2021 Plan as of March 31, 2024, plus any future increases in the number of shares of Class A Common Stock reserved for issuance under our 2021 Plan pursuant to the evergreen provision of our 2021 Plan&#59; </font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">7,997,240 shares of Class A Common Stock reserved for future issuance under our 2021 ESPP as of March 31, 2024, plus any future increases in the number of shares of Class A Common Stock reserved for issuance under our 2021 ESPP pursuant to the evergreen provision of our 2021 ESPP&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares of Class A Common Stock that may become payable pursuant to the terms of the additional consideration arrangements in connection with our acquisition of Cyclica, including 172,497 shares of Class A common stock of additional consideration that had not yet been issued as of March 31, 2024&#59;</font></div><div style="margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">220,557 shares of Class A Common Stock and 600,703 shares of a subsidiary of our company exchangeable for shares of Class A Common Stock that were issued pursuant to the release of shares withheld for potential indemnification claims in connection with our acquisition of Valence after March 31, 2024&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36.7pt;padding-right:0.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any shares of Class A Common Stock that we elect to issue in order to make annual payments in equity in connection with our collaboration agreement with Tempus.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any options are exercised, any restricted stock units are settled, any new awards are issued under our equity incentive plans, or we otherwise issue additional shares of common stock in the future (including shares issued in connection with acquisitions), there will be further dilution to new investors.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125558"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIVIDEND POLICY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on a number of factors, including our financial condition, results of operations, capital requirements, contractual restrictions, general business conditions, and other factors that our board of directors may deem relevant, including restrictions in our current and future debt instruments, our future earnings, capital requirements, financial condition, prospects, and applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125559"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following is a description of the material terms and provisions relating to our capital stock. The following description is a summary that is not complete and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, and to provisions of the Delaware General Corporation Law. Copies of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which may be amended from time to time, have been publicly filed with the SEC.  See &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference&#8221; in this prospectus supplement.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">General</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our authorized capital stock consists of 2,200,000,000 shares of capital stock, $0.00001 par value per share, of which 200,000,000 shares are designated preferred stock and 2,000,000,000 shares are designated common stock.  Of our common stock, 1,989,032,117 shares are designated as Class A Common Stock and 10,967,883 shares are designated as Class B Common Stock. </font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Common Stock</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have two series of authorized common stock, Class A Common Stock and Class B Common Stock. The rights of the holders of Class A Common Stock and Class B Common Stock are identical, except with respect to voting and conversion. </font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Voting Rights</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each holder of Class A Common Stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors, and each holder of Class B Common Stock is entitled to ten votes for each share on all matters submitted to a vote of the stockholders, including the election of directors. The holders of Class A Common Stock and Class B Common Stock vote together as a single class, unless otherwise required by law. Under our amended and restated certificate of incorporation, approval of the holders of a majority of the outstanding shares of our Class B Common Stock voting as a separate class is required to increase the number of authorized shares of our Class B Common Stock. In addition, Delaware law could require either the holders of our Class A Common Stock or Class B Common Stock to vote separately as a single class in the following circumstances&#58;</font></div><div style="padding-left:56pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">if we were to seek to amend our amended and restated certificate of incorporation to increase or decrease the par value of a class of stock, then that class would be required to vote separately to approve the proposed amendment&#59; and</font></div><div style="padding-left:56pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">if we were to seek to amend our amended and restated certificate of incorporation in a manner that alters or changes the powers, preferences or special rights of a class of stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment.</font></div><div style="padding-left:56pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Until the Final Conversion Date (described below), approval of the holders of at least two-thirds of the outstanding shares of our Class B Common Stock voting as a separate class is required to amend, repeal or adopt any provision of the amended and restated certificate of incorporation inconsistent with, or otherwise alter, any provision of the amended and restated certificate of incorporation relating to the voting, conversion, or other rights, powers, preferences privileges, or restrictions of our Class B Common Stock so as to affect them adversely or to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">reclassify any outstanding shares of Class A Common Stock into shares having rights as to dividends or liquidation that are senior to the Class B Common Stock or the right to have more than one vote for each share thereof, except as required by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of Class A Common Stock and Class B Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</font></div><div style="margin-bottom:12pt;text-indent:20.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Dividends</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our Class A Common Stock and Class B Common Stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Liquidation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the event of our liquidation, dissolution, or winding up, holders of our Class A Common Stock and Class B Common Stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Conversion of Class B Common Stock</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock. Shares of Class B Common Stock automatically convert into shares of Class A Common Stock upon sale or transfer except for certain transfers described in our amended and restated certificate of incorporation, including transfers for estate planning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of (i) the seven year anniversary of the first day of trading on Nasdaq of our Class A Common Stock, (ii) the date specified by written consent or agreement of the holders of at least 66 2&#47;3% of our then outstanding shares of Class B Common Stock, (iii) nine months after Dr. Christopher Gibson, our co-founder and Chief Executive Officer, ceases to hold any positions as an officer or director with us or (iv) nine months after the death or disability of Dr. Gibson. We refer to the date on which such final conversion of all outstanding shares of Class B Common Stock pursuant to the terms of our amended and restated certificate of incorporation occurs as the Final Conversion Date.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Rights and Preferences</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Holders of our Class A Common Stock have no preemptive, conversion, subscription, or other rights, and there are no redemption or sinking fund provisions applicable to our Class A Common Stock. Holders of our Class B Common Stock have no preemptive or subscription rights, but have conversion rights. There are no redemption or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">sinking fund provisions applicable to our Class B Common Stock. The rights, preferences and privileges of the holders of our Class A Common Stock and Class B Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.  </font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Fully Paid and Nonassessable</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">All of our outstanding shares of Class A Common Stock and Class B Common Stock are, and the shares of Class A Common Stock to be issued in this offering, upon payment and delivery in accordance with the underwriting agreement, will be fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Preferred Stock</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, up to 200,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of Class A Common Stock and Class B Common Stock. The issuance of preferred stock could adversely affect the voting power of holders of Class A Common Stock and Class B Common Stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in our control or other corporate action.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Anti-takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Certain provisions of Delaware law and certain provisions included in our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Classified Board</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class I, Class II, and Class III. Each class consists of an equal number of directors, as nearly as possible, consisting of one third of the total number of directors constituting the entire board of directors. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Removal of Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Director Vacancies</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">No Cumulative Voting</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Special Meetings of Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, except as otherwise required by law, special meetings of the stockholders may be called only by an officer at the request of a majority of our board of directors, by the Chair of our board of directors or by our Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Advance Notice Procedures for Director Nominations</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders must provide timely notice thereof in writing. To be timely, a stockholder&#8217;s notice generally has to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of our company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although our amended and restated bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of our company.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Action by Written Consent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Amending our Certificate of Incorporation and Bylaws</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the Delaware General Corporation Law, or DGCL. Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the Class A Common Stock and Class B Common Stock, except for any amendment of the above provisions, which would require the approval of a two-thirds majority of our then outstanding Class A Common Stock and Class B Common Stock or the separate approval of a majority of our Class B Common Stock for any increase to the authorized number of Class B Common Stock or two-thirds of our then outstanding Class B Common Stock for certain amendments to our Class B Common Stock or certain reclassifications of our Class A Common Stock described above. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered, or repealed by the board of directors.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Authorized but Unissued Shares</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our authorized but unissued shares of Class A Common Stock, Class B Common Stock, and preferred stock is available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Class A Common Stock, Class B Common Stock, and preferred stock could render more difficult or discourage an attempt to obtain control of our company by means of a proxy contest, tender offer, merger, or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Exclusive Jurisdiction</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim arising pursuant to the DGCL, any action regarding our amended and restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated bylaws further provide that the federal district courts of the United States of America are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. We also note that stockholders cannot waive compliance (or consent to noncompliance) with the federal securities laws and the rules and regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Business Combinations with Interested Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are governed by Section 203 of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an &#8220;interested stockholder&#8221; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (1) prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59; (2) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (a) by persons who are directors and also officers of such corporation and (b) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer)&#59; or (3) at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock of such corporation not owned by the interested stockholder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#8217; and officers&#8217; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive officers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The limitation on liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Registration Rights</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In October 2022, in connection with a private placement of our Class A Common Stock to certain investors, we entered into a registration rights agreement providing for the registration for resale of the shares of Class A Common Stock issued in such transaction. A prospectus supplement to our registration statement (File No. 333-264845), or the Shelf Registration Statement, was subsequently filed in October 2022 to register the resale of the shares of Class A Common Stock purchased by such investors. Such agreement and the registration rights thereunder must remain effective until registrable securities covered by the agreement have been sold by the holders or otherwise transferred and subsequent public distribution does not require registration under the Securities Act. In the event the holders cannot sell their shares due to certain circumstances causing the agreement to be ineffective, we must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price paid by the holder without limit until the agreement is cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In May 2023, in connection with the acquisition of Valence, we entered into a Registration Agreement with certain stockholders of Valence providing for the registration for resale of the shares of Class A Common Stock issued in such transaction as well as shares of Class A Common Stock issuable upon exchange of exchangeable shares of one of our subsidiaries issued in such transaction. A registration statement on Form S-3 (File No. 333-272281) was filed to register the shares for resale by the holders. The registration statement must remain effective for a period of not less than three years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In May 2023, in connection with the acquisition of Cyclica, we entered into a registration agreement providing for the registration for resale of the shares of Class A Common Stock issued in such transaction. A prospectus supplement to the Shelf Registration Statement was subsequently filed in June 2023 to register the shares for resale by the holders. The Shelf Registration Statement must be continuously effective until the earlier of the date that all shares have been sold thereunder or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In July 2023, in connection with a private placement of shares of Class A Common Stock to NVIDIA Corporation, or NVIDIA, we entered into a Registration Rights Agreement providing for the registration for resale of the shares of Class A Common Stock issued in such transaction. A prospectus supplement to the Shelf Registration Statement was subsequently filed in August 2023 to register the resale of the shares of Class A Common Stock issued to NVIDIA. We agreed to use commercially reasonable efforts to keep a registration statement continuously effective until such date that all registrable securities under the agreement have been sold. In the event the holders cannot sell their shares due to certain circumstances causing a registration statement to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">ineffective, we must pay each holder of shares outstanding on the date and each month thereafter 1% of the aggregate purchase price with the maximum payable amount of 5% of the aggregate purchase price. We have also agreed that so long as a registration statement is in effect with respect to such shares of Class A Common Stock issued to NVIDIA, we will provide certain assistance in connection with underwritten offerings if requested by NVIDIA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In November 2023, we entered into a Master Agreement, or the Tempus Agreement, with Tempus pursuant to which Tempus will provide certain services and deliverables to us and license certain data to us. Under the Tempus Agreement, in November 2023, we issued to Tempus an aggregate of 3.2 million shares of our Class A Common Stock in lieu of a cash payment of $22.0 million for the initial license fee owed to Tempus in exchange for the rights granted to us under the Tempus Agreement. We may in the future issue shares as payment for fees under the Tempus Agreement in lieu of cash payment. We have agreed pursuant to the Tempus Agreement to prepare and file a registration statement (or a prospectus supplement to an effective registration statement on Form S-3 that will become automatically effective upon filing with the SEC pursuant to Rule 462(e)) with the SEC, for resale of the shares of Class A Common Stock issued or issuable under the Tempus Agreement. A prospectus supplement to the Shelf Registration Statement was subsequently filed in December 2023 to register for resale the shares of Class A Common Stock issued to Tempus for the initial license fee under the Tempus Agreement. After registration of any shares issued to Tempus under the Tempus Agreement, we have agreed to use commercially reasonable efforts to keep such registration statement effective until such date that all shares issued to Tempus covered by such registration statement have been sold or are able to be publicly sold by relying on Rule 144 of the Securities Act without registration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We has agreed to pay certain expenses in connection with the registration of shares of our Class A Common Stock pursuant to the registration rights described above.</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Listing</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol &#8220;RXRX.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Transfer Agent and Registrar</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The transfer agent and registrar for our Class A Common Stock is Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, NY 11219.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125560"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our Class A Common Stock acquired in this offering by a &#8220;non-U.S. holder&#8221; (as defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the United States Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the Internal Revenue Service, or IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary also does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction or under U.S. federal gift and estate tax rules, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor&#8217;s particular circumstances or to investors that may be subject to special tax rules, including, without limitation&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">banks, insurance companies, regulated investment companies, real estate investment trusts or other financial institutions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons subject to the alternative minimum tax or the tax on net investment income&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax-exempt organizations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pension plans and tax-qualified retirement plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brokers or dealers in securities or currencies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traders in securities that elect to use a mark-to-market method of tax accounting for their securities holdings&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain former citizens or long-term residents of the United States&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who hold our Class A Common Stock as a position in a hedging transaction, &#8220;straddle,&#8221; &#8220;conversion transaction&#8221; or other risk reduction transaction&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who hold or receive our Class A Common Stock pursuant to the exercise of any option or otherwise as compensation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our Class A common stock being taken into account in an &#8220;applicable financial statement&#8221; as defined in Section 451 of the Code&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons who do not hold our Class A Common Stock as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment)&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons deemed to sell our Class A Common Stock under the constructive sale provisions of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a partnership, entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes holds our Class A Common Stock, the tax treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership or other entity. A partner in a partnership or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other such entity that will hold our Class A Common Stock should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our Class A Common Stock through a partnership or other such entity, as applicable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our Class A Common Stock arising under the U.S. federal gift or estate tax rules or under the laws of any state, local, non-U.S. or other taxing jurisdiction or under any applicable tax treaty.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-U.S. Holder Defined</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this discussion, you are a &#8220;non-U.S. holder&#8221; if you are a beneficial owner of our Class A Common Stock that, for U.S. federal income tax purposes, is not a partnership (including any entity or arrangement treated as a partnership) or&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is a citizen or resident of the United States&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income tax regardless of its source&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust (x) whose administration is subject to the primary supervision of a U.S. court and that has one or more U.S. persons, as defined under the Code, who have the authority to control all substantial decisions of the trust or (y) that has made a valid election under applicable Treasury Regulations to be treated as a U.S. person.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distributions</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the section titled &#8220;Dividend Policy,&#8221; we have never declared or paid cash dividends on our Class A Common Stock, and we do not anticipate paying any dividends on our Class A Common Stock following the completion of this offering. However, if we do make distributions on our Class A Common Stock, those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, the excess will constitute a return of capital and will first reduce your basis in our Class A Common Stock, but not below zero, and then will be treated as gain from the sale of stock.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the discussions below on effectively connected income and in the sections titled &#8220;&#8212;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;Foreign Account Tax Compliance Act,&#8221; any dividend paid to you generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. In order to receive a reduced treaty rate, you must provide the applicable withholding agent with an IRS Form W-8BEN or W-8BEN-E or other appropriate version of IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of our Class A Common Stock eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If the non-U.S. holder holds our Class A Common Stock through a financial institution or other agent acting on the non-U.S. holder&#8217;s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends received by you that are treated as effectively connected with your conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, such dividends are attributable to a permanent establishment or fixed base maintained by you in the United States) are generally exempt from the 30% U.S. federal withholding tax, subject to the discussion below in the sections titled &#8220;&#8212;Backup Withholding and Information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reporting&#8221; and &#8220;&#8212;Foreign Account Tax Compliance Act.&#8221; In order to obtain this exemption, you must provide us or our paying agent with a properly executed IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same rates applicable to U.S. persons, net of certain deductions and credits. In addition, if you are a corporate non-U.S. holder, dividends you receive that are effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. You should consult your tax advisor regarding the tax consequences of the ownership and disposition of our Class A Common Stock, including any applicable tax treaties that may provide for different rules.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Disposition of Common Stock</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the discussion below regarding &#8220;&#8212;Backup Withholding and Information Reporting,&#8221; you generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of our Class A Common Stock unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the gain is effectively connected with your conduct of a U.S. trade or business (and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by you in the United States)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">you are an individual who is present in the United States for a period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Class A Common Stock constitutes a United States real property interest by reason of our status as a &#8220;United States real property holding corporation,&#8221; or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding your disposition of, or your holding period for, our Class A Common Stock, unless our Class A Common Stock is regularly traded on an established securities market and you hold no more than 5% of our outstanding Class A Common Stock, directly, indirectly and constructively, at all times, during the shorter of the five-year period ending on the date of the taxable disposition or your holding period for our Class A Common Stock.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our U.S. and worldwide real property interests plus our other business assets, there can be no assurance that we will not become a USRPHC in the future. If we are a USRPHC and either our Class A Common Stock is not regularly traded on an established securities market or you hold, or are treated as holding, more than 5% of our outstanding Class A Common Stock, directly or indirectly, during the applicable testing period, you will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. If we are a USRPHC and our Class A Common Stock is not regularly traded on an established securities market, your proceeds received on the disposition of shares will also generally be subject to withholding at a rate of 15%. We expect our stock to continue to be regularly traded on an established securities market&#59; however, we cannot provide any assurance that our stock will be regularly traded on an established securities market in the future. You are encouraged to consult your own tax advisors regarding the possible consequences to you if we are, or were to become, a USRPHC.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are a non-U.S. holder described in the first bullet above, you will be required to pay tax on the gain derived from the sale (net of certain deductions and credits) under regular U.S. federal income tax rates, and a corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are an individual non-U.S. holder described in the second bullet above, you will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal income tax returns with respect to such losses. You should consult your tax advisor regarding any applicable income tax or other treaties that may provide for different rules. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backup Withholding and Information Reporting</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we must report annually to the IRS the amount of dividends paid to you, your name and address, and the amount of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of dividends on or of proceeds from the disposition of our Class A Common Stock made to you may be subject to information reporting and backup withholding at a current rate of 24% unless you establish an exemption, for example, by properly certifying your non-U.S. status on a properly completed IRS Form W-8BEN or W-8BEN-E or another appropriate version of IRS Form W-8. Notwithstanding the foregoing, backup withholding and information reporting may apply if the applicable withholding agent has actual knowledge, or reason to know, that you are a U.S. person.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Backup withholding is not an additional tax&#59; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Account Tax Compliance Act</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Account Tax Compliance Act, Treasury Regulations issued thereunder and official IRS guidance, or, collectively, FATCA, generally impose a U.S. federal withholding tax of 30% on dividends on, and, subject to the discussion of certain proposed Treasury Regulations below, the gross proceeds from a sale or other disposition of our Class A Common Stock, paid to a &#8220;foreign financial institution&#8221; (as specially defined under these rules), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and, subject to the discussion of certain proposed Treasury Regulations below, the gross proceeds from a sale or other disposition of our Class A Common Stock paid to a &#8220;non-financial foreign entity&#8221; (as specially defined under these rules) unless such entity provides the withholding agent with a certification identifying the substantial direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and backup withholding tax, including under the other exemptions described above. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Prospective investors should consult with their own tax advisors regarding the application of FATCA withholding to their investment in, and ownership and disposition of, our Class A Common Stock.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Treasury Secretary has issued proposed Treasury Regulations, which, if finalized in their present form, would eliminate withholding under FATCA with respect to payment of gross proceeds from a sale or other disposition of our Class A Common Stock. In its preamble to such proposed Treasury Regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed Treasury Regulations until final regulations are issued.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their particular circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing of our Class A Common Stock, including the consequences of any proposed change in applicable laws.</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125561"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDERWRITING</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&#160;&#38; Co. LLC and J.P. Morgan Securities LLC are the representatives of the underwriters.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:80.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Underwriters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br>Shares</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goldman Sachs&#160;&#38; Co. LLC</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256,410</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J.P. Morgan Securities LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256,410</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allen&#160;&#38; Company LLC</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256,410</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,769,230</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below unless and until this option is exercised. Certain of the underwriters may offer and sell shares of our Class A Common Stock through one or more of their affiliates or selling agents.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters have an option to buy up to an additional 4,615,384 shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase 4,615,384 additional shares from us.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Exercise</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Full Exercise</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per Share</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.360750</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.360750</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11,100,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12,765,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares sold by the underwriters to the public will initially be offered at the public offering price set forth on the cover of this prospectus supplement. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $0.216450 per share from the public offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed that we will not (i)&#160;offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Securities and Exchange Commission a registration statement under the Securities Act relating to, any of our securities that are substantially similar to the shares of Class A Common Stock, including but not limited to any options or warrants to purchase shares of common stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii)&#160;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any such other securities, whether any such transaction described in clause&#160;(i) or (ii) above is to be settled by delivery of common stock or such other securities, in cash or otherwise, other than (a)&#160;the shares to be sold pursuant to the underwriting agreement or pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of the underwriting agreement, (b)&#160;our issuance of any shares of stock, options and other awards granted under a Company stock plan or shares issued pursuant to an employee stock purchase plan, (c)&#160;any shares of common stock issued upon the exercise of options or the settlement of options or other awards granted pursuant to the stock-based compensation plans of our company, (d)&#160;the filing by us of any registration statement on&#160;Form&#160;S-8&#160;with the Securities and Exchange Commission relating to the offering of securities pursuant to the terms of such equity plans described herein, (e)&#160;any shares of common stock or other securities issued in connection with a transaction that includes a commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements, intellectual property license agreements, or lending agreements or arrangements) or any acquisition of assets or acquisition of equity of another entity, provided that, in the case of any issuance pursuant to this clause&#160;(e), any recipient of shares of common stock shall have executed and delivered to Goldman Sachs&#160;&#38; Co. LLC and J.P.&#160;Morgan Securities LLC a&#160;lock-up&#160;letter as described in the underwriting agreement, without the prior written consent of Goldman Sachs&#160;&#38; Co. LLC and J.P.&#160;Morgan Securities LLC.  The underwriting agreement does not contain any limitation on our ability to issue shares of common stock or other securities in connection with any transaction that includes a commercial relationship, including joint ventures, marketing or distribution arrangements, collaboration agreements, intellectual property license agreements, or lending agreements or arrangements, or any acquisition of assets or acquisition of equity of another entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, executive officers and certain affiliated holders of our Class A Common Stock (such persons, the&#160;&#34;lock-up&#160;parties&#34;), have entered into&#160;lock-up&#160;agreements with the underwriters prior to the commencement of this offering pursuant to which each&#160;lock-up&#160;party, with limited exceptions, for a period of 45&#160;days after the date of this prospectus supplement (such period, the &#8220;restricted period&#8221;), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of Goldman Sachs&#160;&#38; Co. LLC and J.P.&#160;Morgan Securities LLC, (i)&#160;offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of our common stock, or any options or warrants to purchase any shares of our common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of our common stock (collectively, the&#160;&#8220;lock-up&#160;securities&#8221;), including, without limitation, any such&#160;lock-up&#160;securities now owned or hereafter acquired by the&#160;lock-up&#160;party, (ii)&#160;engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the&#160;lock-up&#160;party or someone other than the&#160;lock-up&#160;party), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any&#160;lock-up&#160;securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of common stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a &#8220;transfer&#8221;), (iii) make any demand for or exercise any right with respect to the registration of any lock-up securities&#160;or (iv) otherwise publicly announce any intention to engage in or cause any action, activity or transaction described in clause&#160;(i), (ii) or (iii) above. Each&#160;lock-up&#160;party has further acknowledged that it has not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or which reasonably could be expected to lead to or result in any transfer during the restricted period and that the foregoing provisions are equally applicable to shares the&#160;lock-up&#160;party may purchase in this offering.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, our directors, executive officers and stockholders may transfer the&#160;lock-up&#160;securities during the restricted period&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bona fide&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estate planning purposes, provided that the donee or donees thereof agree to be bound in writing by the restrictions set forth in the&#160;lock-up&#160;agreements, and provided further that, if required, any public report or filing under Section&#160;16(a) of the Exchange Act shall indicate in the footnotes thereto the nature of the transaction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to any member of the&#160;lock-up&#160;party&#8217;s immediate family or to any trust or other legal entity for the direct or indirect benefit of the&#160;lock-up&#160;party or the immediate family of the&#160;lock-up&#160;party, or if the&#160;lock-up&#160;party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, provided that any such transfer is not a disposition for value, provided that the donee, transferee or distributee agrees to be bound in writing by the restrictions set forth herein, and provided further that no filing under Section&#160;16(a) of the Exchange Act (other than a required filing on Form&#160;5), reporting a reduction in beneficial ownership of shares of common stock, shall be required or shall be voluntarily made during the restricted period&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;by will, other testamentary document or the laws of intestate succession, provided that the beneficiary or the estate of a beneficiary thereof agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transaction shall not involve a disposition for value and that no filing under Section&#160;16(a) of the Exchange Act (other than required filing on Form&#160;5), reporting a reduction in beneficial ownership of shares of common stock, shall be required or shall be voluntarily made during the restricted period&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;in connection with the sale of shares of common stock acquired in the offering (if the&#160;lock-up&#160;party is not one of our officers or directors), or in open market transactions after the offering, provided that no filing under Section&#160;16(a) of the Exchange Act (other than required filing on Form&#160;5), reporting a reduction in beneficial ownership of such shares of common stock, shall be required or shall be voluntarily made during the restricted period&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;if the&#160;lock-up&#160;party is a corporation, partnership, limited liability company, trust or other business entity, by (A)&#160;to another corporation, member, partner, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule&#160;405 as promulgated by the SEC under the Securities Act of 1933, as amended) of the&#160;lock-up&#160;party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the&#160;lock-up&#160;party or affiliates of the&#160;lock-up&#160;party, or (B)&#160;as part of a distribution, transfer or disposition by the lock-up party to its or its affiliates&#8217; directors, officers, employees, managers, managing members, members, stockholders, partners, beneficiaries (or the estates thereof) or other equity holders of the&#160;lock-up&#160;party (or in each case its nominee or custodian)&#59; provided that each distributee and transferee agrees to be bound in writing by the restrictions set forth herein, and provided further that no filing under Section&#160;16(a) of the Exchange Act (other than a required filing on Form&#160;5), reporting a reduction in beneficial ownership of shares of common stock, shall be required or shall be voluntarily made during the restricted period&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;in connection with surrender or forfeiture to us of shares of common stock in connection with the &#8220;net&#8221; or &#8220;cashless&#8221; exercise or settlement of stock options, restricted stock units and other rights to purchase shares of common stock or other awards for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement, or exercise of such awards, in all such cases, pursuant to an equity incentive plan, stock purchase plan or other employee benefit plan, in each case described in this prospectus supplement (or any documents incorporated by reference herein)&#59; provided that, in each case, the underlying shares of common stock shall continue to be subject to the restrictions on transfer set forth in the&#160;lock-up&#160;agreements (other than shares surrendered or forfeited), and provided further that, if required, any public report or filing under Section&#160;16(a) of the Exchange Act shall indicate in the footnotes thereto the nature of the transaction&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;to us in connection with the repurchase by us from the&#160;lock-up&#160;party of&#160;lock-up&#160;securities pursuant to a repurchase right arising upon the termination of the&#160;lock-up&#160;party&#8217;s employment with us&#59; provided that such repurchase right is pursuant to contractual agreements with us&#59; and provided further that, if required, any public report or filing under Section&#160;16(a) of the Exchange Act shall indicate in the footnotes thereto the nature of the transaction&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;to a nominee or custodian of a person or entity to whom a transfer would be permissible under (i), (ii), (iii) or (v) above&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all holders of our capital stock on substantially the same terms for holders of a majority of the voting power of our outstanding shares of capital stock involving a change of control of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-29</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the&#160;lock-up securities shall remain subject to the provisions of the&#160;lock-up&#160;agreements&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;by operation of law pursuant to orders of a court, a qualified domestic order or in connection with a divorce settlement, provided that the transferee or transferees thereof agree to be bound in writing by the restrictions set forth herein, and provided further that no filing under Section&#160;16(a) of the Exchange Act (other than required filing on Form 5), reporting a reduction in beneficial ownership of shares of common stock, shall be required or shall be voluntarily made during the restricted period&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;any transfer or disposition of the&#160;lock-up&#160;securities (including, without limitation, any sale or other exercise of remedies by the pledgee and&#47;or transferee thereto) pursuant to a bona fide loan or pledge that is in effect on the date hereof and has been disclosed in writing to the Representatives and (ii)&#160;the grant and maintenance of a bona fide lien, security interest, pledge or other similar encumbrance of any of the&#160;lock-up&#160;securities to a nationally or internationally recognized financial institution with assets of not less than $10&#160;billion in connection with a loan to the lock-up party&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;that we or the lock-up party, as the case may be, shall provide the Representatives prior written notice informing them of any public filing, report or announcement made by or on behalf of us or the lock-up party with respect thereto&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;that the aggregate number of shares of common stock pledged as collateral during the&#160;restricted period shall not exceed one percent (1%) of the total number of shares of common stock issued and outstanding on the closing date of the offering.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;in connection with the sale of shares of common stock made pursuant to a written 10b5-1 trading plan that complies with&#160;Rule&#160;10b5-1&#160;under the Exchange Act that has been entered into by the lock-up party prior to the date of this agreement&#59; provided that to the extent a public announcement or filing under the Exchange Act, if any, is required of the lock-up party or us regarding any such sales, such announcement or filing shall include a statement to the effect that any sales were pursuant to such trading plan and no other public announcement shall be required or shall be made voluntarily in connection with such sales&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;by exercise on a cash basis of options or other rights granted pursuant to equity incentive plans described in this prospectus supplement (or any documents incorporated by reference herein), and the receipt by the&#160;lock-up&#160;party from us of shares of common stock upon such exercise&#59; provided that, in each case, the underlying shares of common stock shall continue to be subject to the restrictions on transfer set forth in the&#160;lock-up&#160;agreements, and provided further that, if required, any public report or filing under Section&#160;16(a) of the Exchange Act shall indicate in the footnotes thereto the nature of the transaction&#59; or</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;by establishing of a 10b5-1 trading plan that complies with&#160;Rule&#160;10b5-1&#160;under the Exchange Act for the transfer of shares of common stock&#59; provided that (i) such plan does not provide for the transfer of common stock during the restricted period, (ii) no public announcement or filing under the Exchange Act shall be voluntarily made by or on behalf of us or the lock-up party regarding the establishment of such plan during the restricted period and (iii) to the extent a filing under the Exchange Act or other public filing is legally required by or on behalf of the lock-up party or us regarding the establishment of such trading plan, such filing shall include a statement to the effect that no transfer of shares of common stock may be made under such trading plan during the restricted period.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goldman Sachs&#160;&#38; Co. LLC and J.P.&#160;Morgan Securities LLC, in their sole discretion, may release the securities subject to any of the&#160;lock-up&#160;agreements with the underwriters described above, in whole or in part at any time.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol &#8220;RXRX.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering, the underwriters may purchase and sell shares of Class A Common Stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional shares for which the underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Class A Common Stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of Class A Common Stock made by the underwriters in the open market prior to the completion of the offering.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the Class A Common Stock. As a result, the price of the Class A Common Stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the Nasdaq, in the&#160;over-the-counter&#160;market or otherwise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $850,000. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority, or FINRA, up to $15,000.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and&#160;non-financial&#160;activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:30.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors, and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and&#47;or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and&#47;or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and&#47;or publish or express independent research views in respect of such assets, securities or instruments and may at any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time hold, or recommend to clients that they should acquire, long and&#47;or short positions in such assets, securities and instruments.</font></div><div style="margin-top:18pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling Restrictions</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than in the U.S., no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in the European Economic Area </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to each Member State of the European Economic Area (each a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in the United Kingdom </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to the United Kingdom, no shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares that either (i) has been approved by the Financial Conduct Authority, or (ii) is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provision in Regulation 74 of the Prospectus (Amendment etc.) (EU Exit) Regulations 2019, except that offers of shares may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000, or the FSMA&#59; provided that no such offer of shares shall require us or any representative to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, this prospectus supplement is only being distributed to, and is only directed at, and any investment or investment activity to which this prospectus supplement relates is available only to, and will be engaged in only with, persons who are outside the United Kingdom or persons in the United Kingdom (i) having professional experience in matters relating to investments who fall within the definition of &#8220;investment professionals&#8221; in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order&#59; or (ii) who are high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). Persons who are not relevant persons should not take any action on the basis of this prospectus supplement and should not act or rely on it.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Canada </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prospectus Exemptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or subsection 73.3(1) of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ontario), and are permitted clients, as defined in National Instrument 31-103 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 3A.3 of National Instrument 33-105 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwriting Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Switzerland </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-33</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither this document nor any other offering or marketing material relating to the offering, our company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in the Dubai International Financial Centre, or DIFC </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement and the accompanying prospectus relate to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or the DFSA. This prospectus supplement and the accompanying prospectus are intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement or the accompanying prospectus nor taken steps to verify the information set forth herein and has no responsibility for this prospectus supplement or the accompanying prospectus. The shares to which this prospectus supplement and the accompanying prospectus relate may be illiquid and&#47;or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus supplement and the accompanying prospectus you should consult an authorized financial advisor. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Australia </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or Exempt Investors.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As any offering of shares under this prospectus supplement will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-34</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Japan </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Law Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Hong Kong </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder&#59; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, or the CO or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Singapore </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore SFA Product Classification&#8212;In connection with Section&#160;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&#160;309A(1) of the SFA), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA&#160;04-N12&#58; Notice on the Sale of Investment Products and MAS Notice FAA-N16&#58; Notice on Recommendations on Investment Products). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each underwriter has acknowledged that this prospectus supplement and the accompanying prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement and the accompanying prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than&#58; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section 274 of the SFA&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-35</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where the shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor&#59; or </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except&#58; </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA&#59; </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;where no consideration is or will be given for the transfer&#59; </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;where the transfer is by operation of law&#59; </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;as specified in Section 276(7) of the SFA&#59; or </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in China</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement and the accompanying prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be offered or sold to any person for re-offering or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus supplement, the accompanying prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Korea</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA.  None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The securities have not been listed on any securities exchanges in Korea, including, without limitation, the Korea Exchange in Korea.  Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice to Prospective Investors in Taiwan</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Saudi Arabia</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on the Offer of Securities and Continuing Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number 3-123-2017 dated 27 December 2017, as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in the United Arab Emirates</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus supplement does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus supplement and the accompanying prospectus have not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority, Financial Services Regulatory Authority (FSRA) or the Dubai Financial Services Authority (DFSA).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in the British Virgin Islands</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of the Issuer. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in South Africa</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to restrictions under the securities laws of South Africa, no &#8220;offer to the public&#8221; (as such term is defined in the South African Companies Act, No. 71 of 2008 (as amended or re-enacted), or the South African Companies Act) is being made in connection with the issue of the shares in South Africa. Accordingly, this document does not, nor is it intended to, constitute a &#34;registered prospectus&#34; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and&#47;or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 96(1)(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the offer, transfer, sale, renunciation or delivery is to&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent&#59; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the South African Public Investment Corporation&#59; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) persons or entities regulated by the Reserve Bank of South Africa&#59; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) authorised financial service providers under South African law&#59; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) financial institutions recognised as such under South African law&#59; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law)&#59; or </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii) any combination of the person in (i) to (vi)&#59; or </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 96(1)(b) </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information made available in this prospectus supplement should not be considered as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">advice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as defined in the South African Financial Advisory and Intermediary Services Act, 2002.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Bermuda</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda, which regulates the sale of securities in Bermuda. Additionally, non-Bermudian&#160;persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice to Prospective Investors in Israel</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus supplement and the accompanying prospectus are being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&#160;a limited number of persons in accordance with the Israeli Securities Law and (ii)&#160;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&#160;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-38</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125567"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the issuance and sale of our Class A Common Stock offered in this prospectus supplement will be passed upon for us by Wilson Sonsini Goodrich &#38; Rosati, P.C., Seattle, Washington. Davis Polk &#38; Wardwell LLP, Menlo Park, California, is acting as counsel for the underwriters.</font></div><div style="margin-top:24pt;text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125568"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of Recursion Pharmaceuticals, Inc. appearing in Recursion Pharmaceuticals, Inc.&#8217;s Annual Report (Form 10-K) for the year ended December 31, 2023, and the effectiveness of Recursion Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2023, have been audited by Ernst &#38; Young LLP, predecessor independent registered public accounting firm, as set forth in its reports thereon, which conclude, among other things, that Recursion Pharmaceuticals, Inc. did not maintain effective internal control over financial reporting as of December 31, 2023, based on Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework, because of the effects of the material weakness described therein, included therein, and incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.</font></div><div style="margin-top:24pt;text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125569"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION </font></div><div style="text-indent:20pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> internet at the SEC&#8217;s website at&#160;www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. In addition, we maintain a website that contains information about us at&#160;www.recursion.com. The information found on, or otherwise accessible through, this website is not incorporated into, and does not form a part of, this prospectus supplement or the accompanying prospectus or any other report or document we file with or furnish to the SEC.</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed with the SEC a registration statement on Form&#160;S-3,&#160;of which this prospectus supplement and the accompanying prospectus forms a part. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and exhibits and schedules to the registration statement. For further information with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our company and the securities registered hereby, reference is made to the registration statement, including the exhibits to the registration statement. Statements contained in this prospectus supplement and the accompanying prospectus as to the contents of any contract or other document referred to, or incorporated by reference in, this prospectus supplement and the accompanying prospectus are not necessarily complete and, where that contract is an exhibit to the registration statement, each statement is qualified in all respects by the exhibit to which the reference relates.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-39</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i5787c211d1b749ea8a0ca88dd26b0683_125562"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION INCORPORATED BY REFERENCE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC allows us to incorporate by reference much of the information that we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying prospectus is considered to be part of this prospectus supplement and the accompanying prospectus and information we file later with the SEC will automatically update and supersede this information. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus, the accompanying prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement and the accompanying prospectus incorporate by reference the documents listed below and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished pursuant to Items 2.02 or 7.01 of any Current Report on Form&#160;8-K and, except as may be noted in any such Form&#160;8-K, exhibits filed on such form that are related to such information), until the offering of the securities under the registration statement of which this prospectus supplement forms a part is terminated or completed&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Annual Report on </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000019/rxrx-20231231.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2023 filed with the SEC on February 29, 2024&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Quarterly Report on </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183024000052/rxrx-20240331.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-Q</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the quarter ended March 31, 2024 filed with the SEC on May 9, 2024&#59;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the portions of our </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000040/rxrx-20240423.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitive Proxy Statement</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on Schedule&#160;14A filed with the SEC on April 23, 2024, as supplemented by our </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000160183024000066/recursion-proxysupplementx.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supplement to our Definitive Proxy Statement</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> filed with the SEC on May 24, 2024, that are specifically incorporated by reference into our Annual Report on </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000019/rxrx-20231231.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form&#160;10-K</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Current Reports on Form 8-K filed on </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000009/rxrx-20240125.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 31, 2024</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000012/rxrx-20240206.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">February 7, 2024</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000035/rxrx-20240415.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April 16, 2024 (only with respect to Item 5.02)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183024000051/rxrx-20240507.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">May 9, 2024 (only with respect to Item 4.01)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183024000065/rxrx-20240521.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">May 24, 2024 (only with respect to Items 4.01 and 5.02)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183024000076/rxrx-20240603.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">J</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183024000076/rxrx-20240603.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">une 7, 2024</a>,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000091/rxrx-20240626.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">J</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000091/rxrx-20240626.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">une 27, 202</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001601830/000160183024000091/rxrx-20240626.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the description of our Class A Common Stock contained in the Registration Statement on </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312521112361/d146224d8a12b.htm" style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 8-A</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating thereto, filed on April 12, 2021, including any amendment or report filed for the purpose of updating such description.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus supplement is delivered, a copy of the documents incorporated by reference into this prospectus supplement but not delivered with the prospectus supplement. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by requesting them in writing or by telephone from us at the following address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41 S Rio Grande Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salt Lake City, Utah  84101</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Investor Relations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(385) 269-0203</font></div><div style="text-align:justify;text-indent:20pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">You may also access these documents, free of charge on the SEC&#8217;s website at&#160;www.sec.gov&#160;or on our website at www.recursion.com. Information contained on our website is not incorporated by reference into this prospectus supplement, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus supplement or any accompanying prospectus supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.</font></div><div style="text-align:justify;text-indent:20pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-40</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_16"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font id="i973986fb81254410b081b1a10a9dad65_2411"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div style="text-align:center"><img alt="image_3a.jpg" src="image_3a.jpg" style="height:51px;margin-bottom:5pt;vertical-align:text-bottom;width:171px"></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc.</font></div><div style="margin-top:3pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Class&#160;A Common Stock</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Debt Securities</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Depositary Shares</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Warrants</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Subscription Rights</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Purchase Contracts</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Units</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue securities from time to time in one or more offerings, in amounts, at prices and on terms determined at the time of offering. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus, which will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before you invest.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities may be sold directly to you, through agents or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of those securities and the net proceeds we expect to receive from that sale will also be set forth in a prospectus supplement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class&#160;A Common Stock is listed on the Nasdaq Global Select Market under the symbol &#8220;RXRX.&#8221; Each prospectus supplement will indicate whether the securities offered thereby will be listed on any securities exchange.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings. We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our Class&#160;A Common Stock on any securities exchange.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investing in these securities involves risks. Please carefully read the information under the headings &#8220;</font><font style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_3" style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; beginning on page 4 of this prospectus and &#8220;Item 1A &#8211; Risk Factors&#8221; of our most recent report on Form&#160;10-K&#160;or&#160;10-Q&#160;that is incorporated by reference in this prospectus before you invest in our securities.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The date of this prospectus is May&#160;10, 2022.</font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_19"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i00c4424a52df494faf6c54948141893c_2115"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:93.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_1" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">About this Prospectus</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_2" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Summary</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_3" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_4" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Forward-Looking&#160;Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_5" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_6" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Capital Stock</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Debt Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_8" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Depositary Shares</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_9" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Warrants</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_10" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Subscription Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_11" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Purchase Contracts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_12" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Units</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_13" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan of Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_14" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_15" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Experts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_16" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Where You Can Find More Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312522271663/d347287d424b3.htm#tx347287_17" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation by Reference</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i00c4424a52df494faf6c54948141893c_2116"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, as a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 of the Securities Act of 1933, as amended, using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus provides you with a general description of the securities that may be offered. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with the additional information described under the heading &#8220;Where You Can Find More Information.&#8221;</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized anyone to provide you with information that is different from that contained, or incorporated by reference, in this prospectus, any applicable prospectus supplement or in any related free writing prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus and any applicable prospectus supplement or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in the applicable prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</font></div><div style="text-align:center"><font><br></font></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div><div><font><br></font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_22"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:48.00pt 48.00pt 63.84pt 48.00pt"><div style="text-align:center"><font id="ia434253f03b94111989089cf331ac244_8957"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights selected information that is presented in greater detail elsewhere, or incorporated by reference, in this prospectus. It does not contain all of the information that may be important to you and your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including the matters set forth under the section of this prospectus captioned &#8220;Risk Factors&#8221; and the financial statements and related notes and other information that we incorporate by reference herein, including our most recent Annual Report on Form&#160;10-K&#160;and any subsequently filed Quarterly Reports on Form&#160;10-Q.&#160;Unless the context indicates otherwise, references in this prospectus to &#8220;Recursion,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer, collectively, to Recursion Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries taken as a whole.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company industrializing drug discovery by decoding biology. Central to our mission is the Recursion Operating System (OS), a platform built across diverse technologies&#160;that enables us to map and&#160;navigate hundreds of billions of biological and chemical relationships within one of the world&#8217;s largest proprietary biological and chemical datasets, the Recursion Data Universe. Scaled&#160;&#8216;wet-lab&#8217;&#160;biology and chemistry tools are organized into an iterative loop with&#160;&#8216;dry-lab&#8217;&#160;computational tools to rapidly translate&#160;map-based&#160;hypotheses into validated insights and novel chemistry, unconstrained by published literature or human bias. Our focus on novel technologies spanning target discovery through translation, as well as our ability to rapidly iterate between wet lab and dry lab&#160;in-house&#160;and at scale, differentiates us from other companies in our space. Further, our balanced team of life scientists and computational and technical experts creates an environment where empirical data, statistical rigor and creative thinking are brought to bear on our decisions. To date, we have leveraged our Recursion OS to enable three value drivers&#58; i) an expansive pipeline of internally-developed programs, including several clinical-stage assets, focused on genetically-driven rare diseases and oncology with significant unmet need and market opportunities, in some cases expected to be in excess of $1.0&#160;billion in annual sales&#59; ii) strategic partnerships with leading biopharma companies to map and navigate intractable areas of biology, including fibrosis with Bayer and neuroscience with Roche and Genentech, to identify novel targets and translate potential new medicines to resource-heavy clinical development overseen by our partners&#59; and iii) Induction Labs, a growth engine created to explore new extensions of the Recursion OS both within and beyond therapeutics. We are a biotechnology company scaling more like a technology company.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion finished the first quarter of 2022 with a portfolio of clinical stage, preclinical, late discovery and early discovery programs and continued scaling the total number of phenomic experiments to approximately 128&#160;million, the size of its proprietary data universe to over 14 petabytes, and the number of biological and chemical relationships to approximately 247&#160;billion. Data have been generated on the Recursion OS across 44 human cell types, an&#160;in-house&#160;chemical library of approximately 1.3&#160;million compounds, and an</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in silico</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;library of 12&#160;billion small molecules, by a growing team of over 450 Recursionauts that is balanced between life scientists and computational and technical experts.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located at 41 S Rio Grande Street, Salt Lake City, Utah 84101. Our telephone number is (385)&#160;269-0203.&#160;Our website is www.recursion.com. Information contained in, or that can be accessed through, our website is not a part of, and is not incorporated into, this report.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Securities That May Be Offered</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer or sell Class&#160;A Common Stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units in one or more offerings and in any combination. Each time securities are offered with this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and terms of the securities being offered and the net proceeds we expect to receive from that sale.</font></div></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:48.00pt 48.00pt 63.84pt 48.00pt"><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities may be sold to or through underwriters, dealers or agents or directly to purchasers or as otherwise set forth in the section of this prospectus captioned &#8220;Plan of Distribution.&#8221; Each prospectus supplement will set forth the names of any underwriters, dealers, agents or other entities involved in the sale of securities described in that prospectus supplement and any applicable fee, commission or discount arrangements with them.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class&#160;A Common Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer shares of our Class&#160;A Common Stock, par value $0.00001 per share, either alone or underlying other registered securities convertible into our Class&#160;A Common Stock. Holders of our Class&#160;A Common Stock are entitled to receive dividends declared by our board of directors out of funds legally available for the payment of dividends, subject to rights, if any, of preferred stockholders. We have not paid dividends in the past and have no current plans to pay dividends. Each holder of Class&#160;A Common Stock is entitled to one vote per share. The holders of Class&#160;A Common Stock have no preemptive rights.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Each series of preferred stock offered by us will be more fully described in the particular prospectus supplement that will accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or winding up, voting rights and rights to convert into Class&#160;A Common Stock.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depositary Shares</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue fractional shares of preferred stock that will be represented by depositary shares and depositary receipts.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of depositary shares or depositary receipts offered by us will be more fully described in the particular prospectus supplement that will accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or winding up, voting rights and rights to convert into Class&#160;A Common Stock.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer secured or unsecured obligations in the form of one or more series of senior or subordinated debt. The senior debt securities and the subordinated debt securities are together referred to in this prospectus as the &#8220;debt securities.&#8221; The subordinated debt securities generally will be entitled to payment only after payment of our senior debt. Senior debt generally includes all debt for money borrowed by us, except debt that is stated in the instrument governing the terms of that debt to be not senior to, or to have the same rank in right of payment as, or to be expressly junior to, the subordinated debt securities. We may issue debt securities that are convertible into shares of our Class&#160;A Common Stock.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt securities will be issued pursuant to an indenture between us and a trustee to be identified in an accompanying prospectus supplement. We have summarized the general features of the debt securities to be governed by the indenture in this prospectus and the form of indenture has been filed as an exhibit to the registration statement of which this prospectus forms a part. We encourage you to read the indenture.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer warrants for the purchase of Class&#160;A Common Stock, preferred stock, debt securities or depositary shares. We may offer warrants independently or together with other securities.</font></div></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:48.00pt 48.00pt 63.84pt 48.00pt"><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subscription Rights</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer subscription rights to purchase our Class&#160;A Common Stock, preferred stock, debt securities, depositary shares, warrants or units consisting of some or all of these securities. These subscription rights may be offered independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Contracts</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer purchase contracts, including contracts obligating holders or us to purchase from the other a specific or variable number of securities at a future date or dates.</font></div><div style="margin-top:18pt;padding-left:11.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Units</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer units comprised of one or more of the other classes of securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></div><div id="i0890d7c4463a4953bcd09119a35873e9_25"></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51204"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the section in the applicable prospectus supplement captioned &#8220;Risk Factors,&#8221; together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under &#8220;Part&#160;I&#8212;Item&#160;1A&#8212;Risk Factors&#8221; of our most recent Annual Report on&#160;Form&#160;10-K&#160;and in &#8220;Part&#160;II&#8212;Item&#160;1A&#8212;Risk Factors&#8221; in our subsequently filed Quarterly Reports on&#160;Form&#160;10-Q,&#160;each of which are incorporated herein by reference, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51200"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING&#160;STATEMENTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement contain certain statements that constitute &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;likely,&#8221; and similar expressions and variations thereof are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Those statements appear in this prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the sections captioned &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks, uncertainties and assumptions. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus, whether as a result of any new information, future events or otherwise.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus and the documents incorporated by reference in this prospectus may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this prospectus, actual results may differ from the projections.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51201"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise provided in the applicable prospectus supplement, we currently expect to use the net proceeds that we receive from this offering to obtain capital to support our operations and other general corporate purposes. We may also use a portion of the net proceeds to acquire, license or invest in complementary products, technologies or businesses or to facilitate our future access to the public capital markets&#59; however, we currently have no agreements or commitments to complete any such transaction. The expected use of net proceeds of this offering represents our current intentions based on our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Pending these uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51209"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The description of our capital stock is incorporated by reference to&#160;</font><font style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000160183022000012/exhibit43-descriptionofsec.htm" style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;4.3&#160;</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our Annual Report on&#160;Form&#160;10-K&#160;for the fiscal year ended December&#160;31, 2021, filed with the SEC on March&#160;23, 2022.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51212"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt securities will be issued under an indenture between us and a trustee to be identified in an accompanying prospectus supplement. We have summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement of which this prospectus forms a part and you should read the indenture for provisions that may be important to you. In the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including any pricing supplement or term sheet).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered the aggregate principal amount and the following terms of the debt securities, if applicable&#58;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the title and ranking of the debt securities (including the terms of any subordination provisions)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any limit upon the aggregate principal amount of the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the date or dates on which the principal of the securities of the series is payable&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the interest payable on any interest payment date&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the debt securities will be issued in the form of certificated debt securities or global debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the currency of denomination of the debt securities, which may be United States dollars or any foreign currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the designation of the currency, currencies or currency units in which payment of principal of, premium and interest on the debt securities will be made&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any provisions relating to any security provided for the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the debt securities will be convertible into our Class A Common Stock or&#160;non-convertible&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination, if any, of such guarantees.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer and Exchange</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each debt security will be represented by either one or more global securities registered in the name of a clearing agency registered under the Exchange Act, which we refer to as the depositary, or a nominee of the depositary (we will refer to any debt security represented by a global debt security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#8220;certificated debt security&#8221;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221; below, book-entry debt securities will not be issuable in certificated form.</font></div><div style="margin-top:18pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certificated Debt Securities</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</font></div><div style="margin-top:18pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Debt Securities and Book-Entry System</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the depositary, and registered in the name of the depositary or a nominee of the depositary.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Protection in the Event of a Change of Control</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the debt securities protection in the event we have a change in control or in </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation, Merger and Sale of Assets</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person, which we refer to as a successor person, unless&#58;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">we are the surviving corporation or the successor person (if other than us) is a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Event of Default&#8221; means with respect to any series of debt securities, any of the following&#58;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the&#160;30-day&#160;period)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the payment of principal of any security of that series at its maturity&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee, or we and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of us&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any other Event of Default provided with respect to debt securities of that series that is described in the applicable prospectus supplement.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the&#160;non-payment&#160;of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless&#58;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to debt securities of that series&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall send to each securityholder of the securities of that series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt securities.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification and Waiver</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to cure any ambiguity, defect or inconsistency&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221;&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to provide for uncertificated securities in addition to or in place of certificated securities&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to add guarantees with respect to debt securities of any series or secure debt securities of any series&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to surrender any of our rights or powers under the indenture&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to add covenants or events of default for the benefit of the holders of debt securities of any series&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with the applicable procedures of the applicable depositary&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to make any change that does not adversely affect the rights of any holder of debt securities&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act&#59; or</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to conform the indenture to the description of the debt securities set forth in this prospectus or the accompanying prospectus supplement.</font></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then outstanding if that amendment will&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce the principal amount of discount securities payable upon acceleration of maturity&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration)&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">make the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments&#59; or</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">waive a redemption payment with respect to any debt security.</font></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series&#59; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance of Debt Securities and Certain Covenants in Certain Circumstances</font></div><div style="margin-top:6pt;padding-left:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Defeasance</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and&#47;or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.</font></div><div style="margin-top:18pt;padding-left:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defeasance of Certain Covenants</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain conditions&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement&#59; and</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to the debt securities of that series.</font></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to this as covenant defeasance. The conditions include&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">depositing with the trustee money and&#47;or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such deposit will not result in a breach or violation of, or constitute a default under the indenture or any other agreement to which we are a party&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no Default or Event of Default with respect to the applicable series of debt securities shall have occurred or is continuing on the date of such deposit&#59; and</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delivering to the trustee an opinion of counsel to the effect that we have received from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Personal Liability of Directors, Officers, Employees or Stockholders</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our past, present or future directors, officers, employees or stockholders, as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by the laws of the State of New York.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance of the debt securities) irrevocably submit to the&#160;non-exclusive&#160;jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51210"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF DEPOSITARY SHARES</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, at our option, elect to offer fractional shares of preferred stock, or depositary shares, rather than full shares of preferred stock. If we do, we will issue to the public receipts, called depositary receipts, for depositary shares, each of which will represent a fraction, to be described in the applicable prospectus supplement, of a share of a particular series of preferred stock. Unless otherwise provided in the prospectus supplement, each owner of a depositary share will be entitled, in proportion to the applicable fractional interest in a share of preferred stock represented by the depositary share, to all the rights and preferences of the preferred stock represented by the depositary share. Those rights include dividend, voting, redemption, conversion and liquidation rights.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act as depositary under a deposit agreement between us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary shares will be evidenced by depositary receipts issued pursuant to the depositary agreement. Holders of depositary receipts agree to be bound by the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of terms of the depositary shares contained in this prospectus is not complete. You should refer to the form of the deposit agreement, our certificate of incorporation and the certificate of designation for the applicable series of preferred stock that are, or will be, filed with the SEC.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends and Other Distributions</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary will distribute all cash dividends or other cash distributions, if any, received in respect of the preferred stock underlying the depositary shares to the record holders of depositary shares in proportion to the numbers of depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the underlying preferred stock.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a distribution other than in cash, the depositary will distribute property (including securities) received by it to the record holders of depositary shares, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary may, with our approval, adopt another method for the distribution, including selling the property and distributing the net proceeds from the sale to the holders.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidation Preference</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of the voluntary or involuntary liquidation, dissolution or winding up of us, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Withdrawal of Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the related depositary shares have been previously called for redemption, upon surrender of the depositary receipts at the office of the depositary, the holder of the depositary shares will be entitled to delivery, at the office of the depositary to or upon his or her order, of the number of whole shares of the preferred stock and any money or other property represented by the depositary shares. If the depositary receipts delivered by the holder evidence a number of depositary shares in excess of the number of depositary shares representing the number of whole shares of preferred stock to be withdrawn, the depositary will deliver to the holder at the same time a new depositary receipt evidencing the excess number of depositary shares. In no event will the depositary deliver </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fractional shares of preferred stock upon surrender of depositary receipts. Holders of preferred stock thus withdrawn may not thereafter deposit those shares under the deposit agreement or receive depositary receipts evidencing depositary shares therefor.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redemption of Depositary Shares</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we redeem shares of preferred stock held by the depositary, the depositary will redeem as of the same redemption date the number of depositary shares representing shares of the preferred stock so redeemed, so long as we have paid in full to the depositary the redemption price of the preferred stock to be redeemed plus an amount equal to any accumulated and unpaid dividends on the preferred stock to the date fixed for redemption. The redemption price per depositary share will be equal to the redemption price and any other amounts per share payable on the preferred stock multiplied by the fraction of a share of preferred stock represented by one depositary share. If less than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or pro rata or by any other equitable method as may be determined by the depositary.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the date fixed for redemption, depositary shares called for redemption will no longer be deemed to be outstanding and all rights of the holders of depositary shares will cease, except the right to receive the monies payable upon redemption and any money or other property to which the holders of the depositary shares were entitled upon redemption upon surrender to the depositary of the depositary receipts evidencing the depositary shares.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting the Preferred Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt of notice of any meeting at which the holders of the preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts relating to that preferred stock. The record date for the depositary receipts relating to the preferred stock will be the same date as the record date for the preferred stock. Each record holder of the depositary shares on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the number of shares of preferred stock represented by that holder&#8217;s depositary shares. The depositary will endeavor, insofar as practicable, to vote the number of shares of preferred stock represented by the depositary shares in accordance with those instructions, and we will agree to take all action that may be deemed necessary by the depositary in order to enable the depositary to do so. The depositary will not vote any shares of preferred stock except to the extent that it receives specific instructions from the holders of depositary shares representing that number of shares of preferred stock.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Charges of the Depositary</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will pay charges of the depositary in connection with the initial deposit of the preferred stock and any redemption of the preferred stock. Holders of depositary receipts will pay transfer, income and other taxes and governmental charges and such other charges (including those in connection with the receipt and distribution of dividends, the sale or exercise of rights, the withdrawal of the preferred stock and the transferring, splitting or grouping of depositary receipts) as are expressly provided in the deposit agreement to be for their accounts. If these charges have not been paid by the holders of depositary receipts, the depositary may refuse to transfer depositary shares, withhold dividends and distributions and sell the depositary shares evidenced by the depositary receipt.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment and Termination of the Deposit Agreement</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement between us and the depositary. However, any amendment that materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the </font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amendment has been approved by the holders of a majority of the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all outstanding depositary shares have been redeemed&#59; or</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the holders of depositary shares.</font></td></tr></table></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Resignation and Removal of Depositary</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary may resign at any time by delivering to us notice of its election to do so, and we may remove the depositary at any time. Any resignation or removal of the depositary will take effect upon our appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must be a bank or trust company having its principal office in the United States and having the requisite combined capital and surplus as set forth in the applicable agreement.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary will forward to holders of depositary receipts all notices, reports and other communications, including proxy solicitation materials received from us, that are delivered to the depositary and that we are required to furnish to the holders of the preferred stock. In addition, the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation of Liability</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor the depositary will be liable if either is prevented or delayed by law or any circumstance beyond its control in performing its obligations. Our obligations and those of the depositary will be limited to performance in good faith of our and its duties thereunder. We and the depositary will not be obligated to prosecute or defend any legal proceeding in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. We and the depositary may rely upon written advice of counsel or accountants, on information provided by persons presenting preferred stock for deposit, holders of depositary receipts or other persons believed to be competent to give such information and on documents believed to be genuine and to have been signed or presented by the proper party or parties.</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51202"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF WARRANTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue warrants to purchase debt securities, preferred stock, depositary shares or Class&#160;A Common Stock. We may offer warrants separately or together with one or more additional warrants, debt securities, preferred stock, depositary shares or Class&#160;A Common Stock, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. If we issue warrants as part of a unit, the applicable prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the following terms of any warrants&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the specific designation and aggregate number of, and the offering price at which we will issue, the warrants&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the currency or currency units in which the offering price, if any, and the exercise price are payable&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the warrants are to be sold separately or with other securities as parts of units&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the warrants will be issued in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any applicable material U.S. federal income tax consequences&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the designation and terms of any equity securities purchasable upon exercise of the warrants&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon exercise of the warrants&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if applicable, the designation and terms of the debt securities, preferred stock, depositary shares or Class&#160;A Common Stock with which the warrants are issued and the number of warrants issued with each security&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if applicable, the date from and after which any warrants issued as part of a unit and the related debt securities, preferred stock, depositary shares or Class&#160;A Common Stock will be separately transferable&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of preferred stock, the number of depositary shares or the number of shares of Class&#160;A Common Stock purchasable upon exercise of a warrant and the price at which those shares may be purchased&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">information with respect to book-entry procedures, if any&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the antidilution provisions, and other provisions for changes to or adjustment in the exercise price, of the warrants, if any&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any redemption or call provisions&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or exercise of the warrants.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51211"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SUBSCRIPTION RIGHTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue subscription rights to purchase our Class&#160;A Common Stock, preferred stock, debt securities, depositary shares, warrants or units consisting of some or all of these securities. These subscription rights may be offered independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms relating to the offering, including some or all of the following&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the price, if any, for the subscription rights&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the exercise price payable for our Class&#160;A Common Stock, preferred stock, debt securities, depositary shares, warrants or units consisting of some or all of these securities upon the exercise of the subscription rights&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of subscription rights to be issued to each stockholder&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number and terms of our Class&#160;A Common Stock, preferred stock, debt securities, depositary shares, warrants or units consisting of some or all of these securities which may be purchased per each subscription right&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the extent to which the subscription rights are transferable&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of the subscription rights&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed&#59; and</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by us in connection with the offering of subscription rights.</font></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The descriptions of the subscription rights in this prospectus and in any prospectus supplement are summaries of the material provisions of the applicable subscription right agreements. These descriptions do not restate those subscription right agreements in their entirety and may not contain all the information that you may find useful. We urge you to read the applicable subscription right agreements because they, and not the summaries, define your rights as holders of the subscription rights. For more information, please review the forms of the relevant subscription right agreements, which will be filed with the SEC promptly after the offering of subscription rights and will be available as described in the section of this prospectus captioned &#8220;Where You Can Find More Information.&#8221;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51207"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF PURCHASE CONTRACTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description summarizes the general features of the purchase contracts that we may offer under this prospectus. Although the features we have summarized below will generally apply to any future purchase contracts we may offer under this prospectus, we will describe the particular terms of any purchase contracts that we may offer in more detail in the applicable prospectus supplement. The specific terms of any purchase contracts may differ from the description provided below as a result of negotiations with third parties in connection with the issuance of those purchase contracts, as well as for other reasons. Because the terms of any purchase contracts we offer under a prospectus supplement may differ from the terms we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the summary in this prospectus.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incorporate by reference into the registration statement of which this prospectus is a part the form of any purchase contract that we may offer under this prospectus before the sale of the related purchase contract. We urge you to read any applicable prospectus supplement related to specific purchase contracts being offered, as well as the complete instruments that contain the terms of the securities that are subject to those purchase contracts. Certain of those instruments, or forms of those instruments, have been filed as exhibits to the registration statement of which this prospectus is a part, and supplements to those instruments or forms may be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific or variable number of our securities at a future date or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate holders to sell to us, a specific or varying number of our securities.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we offer any purchase contracts, certain terms of that series of purchase contracts will be described in the applicable prospectus supplement, including, without limitation, the following&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the price of the securities or other property subject to the purchase contracts (which may be determined by reference to a specific formula described in the purchase contracts)&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the purchase contracts are issued separately, or as a part of units each consisting of a purchase contract and one or more of our other securities, including U.S. Treasury securities, securing the holder&#8217;s obligations under the purchase contract&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any requirement for us to make periodic payments to holders or vice versa, and whether the payments are unsecured or&#160;pre-funded&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any provisions relating to any security provided for the purchase contracts&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the purchase contracts are to be prepaid or not&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the securities subject to purchase under the purchase contract&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a discussion of certain U.S. federal income tax considerations applicable to the purchase contracts&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the purchase contracts will be issued in fully registered or global form&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any other terms of the purchase contracts and any securities subject to such purchase contracts.</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51205"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF UNITS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue units comprising two or more securities described in this prospectus in any combination. For example, we might issue units consisting of a combination of debt securities and warrants to purchase Class&#160;A Common Stock. The following description sets forth certain general terms and provisions of the units that we may offer pursuant to this prospectus. The particular terms of the units and the extent, if any, to which the general terms and provisions may apply to the units so offered will be described in the applicable prospectus supplement.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each unit will be issued so that the holder of the unit also is the holder of each security included in the unit. Thus, the unit will have the rights and obligations of a holder of each included security. Units will be issued pursuant to the terms of a unit agreement, which may provide that the securities included in the unit may not be held or transferred separately at any time or at any time before a specified date. A copy of the forms of the unit agreement and the unit certificate relating to any particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the unit agreement and the related unit certificate, see the section of this prospectus captioned &#8220;Where You Can Find More Information.&#8221;</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prospectus supplement relating to any particular issuance of units will describe the terms of those units, including, to the extent applicable, the following&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the designation and terms of the units and the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any provision for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units&#59; and</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whether the units will be issued in fully registered or global form.</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51206"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell securities&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">through underwriters&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">through dealers&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">through agents&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">directly to purchasers&#59; or</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">through a combination of any of these methods of sale.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing securityholders.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may directly solicit offers to purchase securities or agents may be designated to solicit such offers. We will, in the prospectus supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of the securities may be effected from time to time in one or more transactions&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">at a fixed price or prices that may be changed from time to time&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">at market prices prevailing at the time of sale&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">at prices related to such prevailing market prices&#59; or</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">at negotiated prices.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities, including the following&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the name of the agent or any underwriters&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the public offering or purchase price&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if applicable, the names of any selling securityholders&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any discounts and commissions to be allowed or paid to the agent or underwriters&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all other items constituting underwriting compensation&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any discounts and commissions to be allowed or paid to dealers&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any exchanges on which the securities will be listed.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any underwriters or agents are utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with them.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a dealer is utilized in the sale of the securities in respect of which the prospectus is delivered, we will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale.</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we offer securities in a subscription rights offering to our existing securityholders, we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agents, underwriters, dealers and other persons may be entitled under agreements that they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters and other persons acting as agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing relationships with, engage in other transactions with, and&#47;or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may over-allot in connection with the offering, creating a short position for their own accounts. In addition, to cover over-allotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under&#160;Rule&#160;15c6-1&#160;of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.</font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51213"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the securities offered hereby will be passed upon for us by Wilson Sonsini Goodrich&#160;&#38; Rosati, P.C., Seattle, Washington. Additional legal matters may be passed on for us, or any underwriters, dealers or agents by counsel we will name in the applicable prospectus supplement.</font></div><div style="margin-top:24pt;text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51203"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of Recursion Pharmaceuticals, Inc. appearing in Recursion Pharmaceuticals, Inc.&#8217;s Annual Report (Form 10-K) for the year ended December 31, 2021, have been audited by Ernst &#38; Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the reports of Ernst &#38; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing.</font></div><div style="margin-top:24pt;text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51208"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Copies of certain information filed by us with the SEC are also available on our website at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">https&#58;&#47;&#47;www.recursion.com&#47;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Information accessible on or through our website is not a part of this prospectus.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus and any prospectus supplement is part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities that we are offering. Forms of any indenture or other documents establishing the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under cover of a Current Report on Form&#160;8-K&#160;and incorporated in this prospectus by reference. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should read the actual documents for a more complete description of the relevant matters.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font id="i46d3716930064fe884b701aac6ac2ed2_51199"></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC allows us to incorporate by reference much of the information that we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated by reference in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished pursuant to Items 2.02 or 7.01 of any Current Report on&#160;Form&#160;8-K&#160;and, except as may be noted in any such&#160;Form&#160;8-K,&#160;exhibits filed on such form that are related to such information), until the offering of the securities under the registration statement of which this prospectus forms a part is terminated or completed&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183022000012/rxrx-20211231.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form&#160;10-K</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the year ended December&#160;31, 2021&#59;</font></div></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">our Quarterly Report on Form&#160;10-Q&#160;for the quarter ended March&#160;31, 2022&#59;</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the portions of our&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000160183022000017/rxrx_proxystatement2022.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitive Proxy Statement</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;on Schedule 14A (other than information furnished rather than filed) that are incorporated by reference into our Annual Report on&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183022000012/rxrx-20211231.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on April&#160;28, 2022&#59;</font></div></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Current Reports on Form&#160;8-K&#160;filed on&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000119312522004996/d247888d8k.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 10, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000119312522063656/d304080d8k.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 3, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000119312522078973/d317757d8k.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 18, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000160183022000011/rxrx-20220323.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 23, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1601830/000119312522100999/d336385d8k.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">April&#160;11, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The description of our Class A Common Stock contained in the Registration Statement on&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1601830/000119312521112361/d146224d8a12b.htm" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form&#160;8-A</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;relating thereto, filed on April&#160;12, 2021, including any amendment or report filed for the purpose of updating such description.</font></div></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41 S Rio Grande Street</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salt Lake City, Utah 84101</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Investor Relations</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(385)&#160;269-0203</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">30,769,230 Shares</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_4a.jpg" src="image_4a.jpg" style="height:125px;margin-bottom:5pt;vertical-align:text-bottom;width:362px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Class A Common Stock </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:19pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:181.85pt;padding-right:181.85pt;text-align:center;text-indent:-18pt"><font><br></font></div></td></tr></table></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:177.35pt;padding-right:177.35pt;text-align:center;text-indent:-9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:115%">&#160;</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">June 26, 2024</font></div><div style="margin-top:2pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Goldman Sachs&#160;&#38; Co. LLC</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:-8.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">J.P. Morgan </font></div></td></tr></table></div><div style="margin-top:2pt;text-align:center"><font><br></font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Allen &#38; Company LLC</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exhibit107-filingfeetable.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iee5517d9297a40c0b8862a6259814b18_1"></div><div style="min-height:92.88pt;width:100%"><div style="margin-top:12pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 107</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Pursuant to Rule&#160;424(b)(5)<br>Registration No.&#160;333-264845</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calculation of Filing Fee Tables</font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">424(b)(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Form Type)</font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 1 &#8211; Newly Registered Securities and Carry Forward Securities</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CALCULATION OF REGISTRATION FEE</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Security Type </font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Security Class Title </font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Fee Calculation or Carry Forward Rule</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Amount<br>registered</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Proposed<br>maximum<br>offering<br>price per Unit</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Maximum<br>aggregate<br>offering price</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Fee Rate</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount of<br>registration fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="27" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Newly Registered Securities</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.2pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fees to be Paid </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.2pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity </font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.2pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Class A Common Stock, par value $0.00001 per share</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">457(r)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,384,614</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6.50</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$229,999,991.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">0.00014760</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$33,948.00</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fees Previously Paid </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">-</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">-</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td></tr><tr><td colspan="27" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Carry Forward Securities</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carry Forward Securities</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">-</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.4pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">-</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">-</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:111%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$229,999,991.00</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$33,948.00</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Total Fees Previously Paid</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 2.67pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">0</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Total Fee Offsets</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 2.67pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:111%">0</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="padding-left:7.4pt;padding-right:7.4pt"><font><br></font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 2.67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Net Fee Due</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.65pt;padding-right:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$33,948.00</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The prospectus supplement to which this exhibit is attached is the final prospectus supplement for the related offering.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registration fee of $33,948.00 is calculated in accordance with Rules 456(b) and 457(r) of the Securities Act. Represents deferred payment of the registration fees in connection with the registrant&#8217;s Registration Statement on Form S-3ASR (Registration No. 333-264845) filed on May 10, 2022. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes 4,615,384  shares of Class A Common Stock that the underwriters have an option to purchase.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-indent:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.88pt;width:100%"><div style="margin-bottom:12pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:7pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN=PQZYIOVV%O^6J_]]"E9AR/L6:*9YB\?,*?4D!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGLP3@L6SO,A/&S'>J_Q2_:\D\8?LVZ]XST)/%7PL6TNK$VVK:EI"2M=03O\
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MHHH-26SO&T^^M;Q$65[:9)Q&W1BK X/UQ7N_Q2^+WBW2ET?Q#X?UF.#PSK<
M:W7[+&?(F4 20GCJ#R/8FO Z^D_@]%#)\ U$T\<,?]J3[_,TIK[:"HR0J_ZL
M@?Q5C*25I-7Z'PO$<8494<3.*E:7+9JZ::^>MUV/+U_:!\?Q\C78U_[=(O\
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MMN"L-P\2F2,'J%8C(S[5IT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M( ]<T ?&W@/]AG6/!_C+PE>S>+--N=&\,:[/K5N8](5=1OC*9"1=7.<N1YA
M(XP!GI7O?P#^$+_!?PKJ^CR:F-5-]KE]JXE$>S8+B4OLQWVYQFO4-PW8SS7#
MZQ\3-.T+Q1J6DZA8ZA:6>GZ4VKW&M20?Z"L:DAD\S/+@ G;CI0!\=_!O]F/X
MA?$;P+JN@^(?%<NA?#NZ\9WFIWGAN;30MY*D=WYB(DQ/$3LJMTSZ5T?[27[/
M/B'1_!VL_P#"-W]U=:EXJ^(^EZU#-9VF]M*12$WE?XE3:"2>QKZ#\3?M >'M
M!T_X>:A8B37-.\;:E#I^GW=H0$42QM(LK9YVX7Z\UZG'(LBAD8,/53D4 ?+R
M?L=ZCXXL?B-<?$[Q?_PD7B+QAIL.D"\TRS6UAL+:%M\7EQY.6\S#MG@XQ5[P
MG^S7XSM_"_B30/$7B/PS-::AHDND6]QHOA]+2XW,NT32N#DG'55P#7T@TT<>
M SJI8[1D@9/I1)<1P[?,D6/<<#<P&3Z4 ?.+?LASLN/^$E4?\6Y_X0/_ (]O
MXL8^T]?_ !VM:Z_9?74+CX4_:]:\ZS\%Z7<Z7<P^3@WRS6WD$@Y^3'6O5]8\
M?:!X?\4:%X=U'4X;76=;\W^S[1R=T_E*&DQ] 1UK?,T:R+'YBAV&57(R1["@
M#YI^"/[+?BGX-ZMHNG0>(O#NH>#M%9EM?,\/QC57AYV1O<>JY'S@9.*]-^)7
MP??X@?$;X=>*%U,6:^$[JYN6MO+W?:?-A,6,_P .,YKTQIHX\!G4$G:,GJ?2
MN;_X6)X?_P"$ZE\(C4X6\1QV/]I-IRY\S[/OV;_3[W&.M 'A]O\ LASP_!'P
MWX!_X292^D^*U\2&^^S<2 7;S^3MSQ]_;GVKZ:KDO ?CF+QQX936SINH:%&T
MTL/V;6(?(F&QRFXJ3T.,@]P16/\ $+XO6'P[\9> O#UU97%W/XOU"33[::$C
M9 R1&3<^>Q QQ0!Z+17EGQT^.$'P3T?1'CT2\\2ZYKVHII>E:/8ND<ES.RLV
M-SD*H 4DDFN[TG4I+K3;&:[MCI]Y/$LCV,KJSQ,1DKD'!P>,CB@#8HJ)YD3
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M\@6!(Y!&JL_S% .%+<XQ7Z#WG@GP]J5FEC>:#IMW8I)YR6LUG&\2R$Y+A2N
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MMV2#AL[2,#GBO/?VYO@OJOQD^-_P&T^&RUH:"NI7*:EJNAL\4MBC(,2>:O\
MJSGO7A&C>$_B=\"_@G\3OAYIGPX?7M1T;QA#=IXEO=&_M![[3Y"Q^UJC\3SQ
M@#Z;SZ5Q'RA]]:+^TM\+O$'@NY\76/CO1KGPW:SK:W&I+< 10RL<*CYY4D],
MU6O/VIOA-I_@]?%-U\0=#C\/M=O8)?\ VD%'G3[\:XY8C(S@5^:=U\'_ !]X
MD^%/[0/E>$?$M[%XBU?0[JR%[HHL9KV-9AYD@MX_E3"Y) Z \U['^U5\!]4\
M _$KX0^)/"WA?5+#P#H^CRV=U'X5T6*_EL+IUYD:U<88L, L1GY: /T'\/\
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M*** "BBB@ HHHH **** "BBB@ HHHH 1JSM8UJQT&Q>\O[F.TMHQEI)&P/\
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M)7[=%[\(]>A_X2?X5:_I7A3[5;V4^O7-Y;J8Y)0O*V^?,=%+;2P[@URW@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPJO9R>R#VD3I_P#A[S\ ?^?S7/\ P6-_C1_P]Y^ /_/YKG_@L;_&N8_X=C_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"!R5!QO/N#U]J^<<GUK]5/VB/ ,-GJ!U9+</IVI@PW<>/EWD8R?J/U%?F?\
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M:7/-W95:M.O/GJ.[/G[XY_ O7OB1\>/@UXOT^2U_L;PG=74FIPW#'?)'+%L
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MM?>%% 'YQ:7^P+\0_&&K?$8:NOA_X:Z#XCT:6R;1?#-W-<65Y?%]T=TT3<1
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MZQ/K0!\0?\%./!>G>%?V7[V>S:1WN/$%AG>V=G[T':*^V/!7_(GZ%_UX0?\
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MO+MK/P[I]P,P/<*,RWLP_P">4*_-Z$XKPIHVEQ&GWY"$7ZDX'\Z^M_B=<?\
M"M?A[XB&GGRI-'TNQ\*:>R<>7)<)Y]Y(/]I@0N:X,5)V5..\CS,;.5HTX[R_
MX!POBWXO33>+CX3\%Z\;674KI;75_&UX<7=]*3ARK_\ +&W4Y"JN.!6-X3^$
M>G1?M*:=X3UO7;/7K.WF^U37RS;H[O:GF"'<QZL0%//>MSX:_"GPEH_P_LM?
M\3))XL;Q!+%%HFDZ*K+?_:HFW2Q$,-NS PQYK6U3P+X!^+FD^*AX<L&^'OBW
M2+HZCJ]GK2L?LMNB;2EN$'3=C(QG)KA]I"G[D+I;-VZ]SSO:0IWA&Z5K-VZ]
M^_D<1\1O@UKO@VUUOQO'J>CV!AU("XTO0[W,VF&5B8D+(<9QC@=*Z'X7?&JZ
M\6ZUINE>)]56P\1QXAT7QAM DCD/"VU[VF@?[IW<C-<_\-?B/X9C\ Z?X&U;
MPI=>(+]M;-Y:QI=^1:WLTF$0W&!N(7L :N?'/X*ZE#XV\27OA+PE?6GA;2U1
M+F:&-A LRH/.,6X[F0-GD9Z5;M)>SGOK9Z>1H[37LJFCUM+1::%;X]> 8[%E
M\6V.EKHT<UX^GZYH\?W-/U!>3L_Z92CYT^M>/5]::7<'XJ?#&*XNCYL_BCPQ
M<07+'^+4=-.Z*;_>,8P37R1$_F1JW<C-=F%FW%PEO$[L%4E*#ISWCH/HHHKN
M/2"O=OV._C5)\(_BA;V%[,1X>UYUMKI6/RQ2DXCE_,[3[&O"::REEX)5NH8=
M0>QKEQ%*-:FX2V9QXBC'$4Y4I[,_<6-@RAAR"*=7BW[)OQ.;XJ?!C1=1N)-^
MI6J_8;SGGS(^,GZC!_&O9?NXK\[J4W3FX/='Y36IRHU)4Y;IV)ZS]7U2+1=*
MO=0G#&&TA>=]HR=JJ6./P%7ZY_Q]EO OB+"EC_9MS\J]3^Z;BLC$\+^&?[;G
MA[X@:YX4L[[PIXC\+6'BYWC\/ZOJML!::A(N?W:NI.UB%) /6OH"Q\2:3J5]
M/96>J65W>0?ZVW@N$>2/_>4'(_&OB7]E'X!ZQXB^#OPI\;>,O$]]KND^%;.;
M5-"\(6]BML(;C]ZJF1\[I' )"YQR:\N^"?B:R\2?M'?!G6= T30_"EQ>7>IQ
M:IHNA6ETM[:Q&,D1ZC/)\LC%AG!Y!]J /T'\=?&#PA\.?#.JZ]KFO6=O8:;
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M);=CZCO7#1_ W1;S]G/P_P"-#I.J1>+[WXG2:5+?PRSI,E@\Y5HT /R*5)Y
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M0/7%:'PK^-?@OXW:#)J_@CQ#::[91/Y4IMV^>%_[KJ>5/U%?'?B;5/#&@_\
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MD**** "G0_ZY/K3:=%_K$^M 'R+_ ,%8O^353_V'M/\ _1HKZV\%?\B;H/\
MUX0?^BUKY)_X*Q?\FJG_ +#VG_\ HT5];>"O^1-T'_KP@_\ 1:T ;5%%% 'R
M%^T0H_X3CQ!QUM!_Z :^+!7V9^T1=9\9>)G[1V^W\D_^O7QG7WN0_P .7JC\
M-XX:]O!>3_,.PKZT_94<_P!O^%?^N4@_2ODOL*^L/V86$.O^#_\ :5A^8-;Y
M_P#P(^IS<$_[U+T/MJ2-9E*NJNIZJPR*Y37OA3X6\1;FN])@$I_Y:PCRV_,5
MV%)M-?G9^]<J>YXEK'[,.F7&YM,U.YLSV28"1?SZUQ>K?LW^*;'<;.>SU!!T
MPQ1C^=?4.VCFJYF9.C%GQ?J7PS\5Z/DW.A784?Q1+O'Z5SMQ:SV;%9[>:!AV
MDC(K[RVGUJM=:=;7RXN+:&<?]-(PW\ZKF,W071GP@&5NA%.K[,U#X8^%=4R;
MC0K,D]TCV'],5SU]^SWX.O,E+2>U/_3&8_US3YD1[%GRI17T9>?LOZ/)G[+J
M]Y!_OA7']*Q+S]EVZ7/V77HV]I8"/Y&GS(CV<^QX=17K5U^S3XGASY-Y83C_
M 'F7^E9-Q\ ?&EOG;8P3?]<YQ_6G=$^SEV/.Z*[&X^#OC.U^]H,[#_IFRM_6
MLZ;X>>*+?_6:!?#Z19_E1=$\K['/T5;U#1]0TG8+ZQN+/?\ =\^,KN^F:J4Q
M!1110 A /!&175>#?B9K_@>0?V?>&2US\UI<$M&?IZ?A7+=6"CEF. HY)^E=
M]X1^"?B7Q9ME>W_LJR/_ "VNP0Q'LO6D[=2H\U_=/:/ _P >-$\5-':WS?V3
MJ+<>7,?W;G_9;^AKT]?;D5YUX-^!OASPGY<\D']J7R\^?= $ ^JKT%>C+@8
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MK5:6W>$ L!CIUH CHHHH *=%_K$^M-I8_P#6)]: /D;_ (*Q?\FJG_L/:?\
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MP&2!@$]:_2G^P=.CL;FR&G6OV2Z9FGM_(7RY2WWBRXPQ/?/6F77AW2M0T?\
MLJYTRSN-+V"/[#+ K0[1T781C ],4 >"?L3^'[SP_P"$?%=M_P )7H?B+0VU
MEY-,L= O9;RWTF,HI:V$LGS$!OF [;J^5+?Q]H^K?M#?#WQ%X4L8?#6H7OQ!
M;2[SSM;N+C6;R'>R2BYMS\D<)(X4]!C%?I5HOAW2O#-F++1]-M-*LU.1;V4"
MPQ@^NU0!5./P3X=BU:;54T#3$U.5Q+)>+9QB9G'1B^,DCUS0!\':#\-],U;X
M2_M-_$2^GU+4?$UIJ/B'3;-KF[D>&UMP@^2.+.WG)[>E9/P';P5HWQ&^!+?"
M;Q'?ZMJVIZ!=_P#"90&]EG'V=;4%7N48XC=9>%X!XQ7Z)+HNGQVMQ;)I]JMO
M=,SSPK"H25F^\6&,,3WSUJMI/@_0M#O+J[TS1=/TVZN@%GFM;5(WE Z!BH!(
M^M 'YK0^&_"'B3P+^S!XE^(4TLUBVO:Q87^K:A>2HJQB6X,2N^?E^<  \=,5
MZ?HOAGPW)\3?VD/B-XC37M>C\%W"#2M/T^^E40P_8PS>0@.-[#C=S@5]LW7@
M_0=0TE-*NM$T^YTQ7\U;*6UC:$-G.X(1C.23G'>KMOH]C9_:#!96\/VG'G^7
M$J^;@8&[ ^;CCGM0!^9WPF\;1Z+\0M?N/!TEAX:L-1^&.HZK+I_AW6)]3,5P
MJAH99S)P+E=W.VF?LJPV?B3Q%%XP\./9Z7XGTGP1<^5I;:[)>7>M:HZ%OMGD
ML<?*,CIG)QCBOT!\6?!/PCXJ\$Z_X771;71['6;26SGFTF!+:8+(/F*LH&">
M/KCFO/OAW^R;'X4\<>%O$^O>,-0\6W7A2SDL="AFL[>U2UC=-A+>4@,C;0!D
MG'?% 'RW^R/I=_K7C#X5>)+3QMX7TSQ%*9F\26PU>ZFUC6RR-YL-Q;R#8CHX
MSQC;CBOTKKG;/P/X=T_6I-8M=!TRVU>3)>_ALXUG;/7+@;CGZUT5 !1110 4
M444 %%%% !1110 4444 %%%% !1129% "T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\,_MN?
M\GA?LL?]AJ7_ -"2ON:OSH_X*>?$"U^$_P ;O@!XQOK.;4+'1[VXN9[:W8+)
M(@*9"D]\4 ?>NFWDUY'?&:\M+H+<,(OLI^XG97_VJM5^;_A?_@K!\+O";7K6
MW@[Q7<&Z;)\QHAM / X[^];O_#YCX;_]"%XF_P"^XJTDHQDTG=&=.4I13DK,
M_0.BOS\_X?,?#?\ Z$+Q-_WW%4<W_!9;X=E?W?@+Q,#[R15F:'Z#=>.U1PV,
M4=O-!!;1;75LPL,(Y(Z'VK\]?^'RG@/_ *$3Q)_W\CIT?_!9CP'&V?\ A _$
M;>QDCH ^\%T^]AM8;=?#.EM B[0GF*0O/09'2KL-QK%FJQVVB6<,9.66.=5
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MD;[II:* /S3_ &]/A&W@OXD1>++.';I7B#_7%1\L=TH^;/\ O#GZU\]>"_\
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M3M1?6XOM"PVS$3S30!<H %+ $\XZT ?<E%?#?@__ (*::5XF\<:!%+X6BM?
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M_&OJ/_AGOX:_]"1HW_@*M'_#/?PV_P"A*T;_ ,!5HN!\N#PC^R)_T*_AP_\
M;-_\:R=)^'O[*FFI/'-I6@7ZM(SQM+$VY5)R%//:OKG_ (9[^&W_ $)6C?\
M@*M'_#/?PV_Z$K1O_ 5:+@?*O_"&_LF_]"YX<_[]-_C1_P (;^R;_P!"YX<_
M[]-_C7U7_P ,]_#;_H2='_\  5:3_AGOX;_]"5H__@*M%Q6/E7_A#?V3?^A<
M\.?]^F_QJ#3O /[)MK<7<MQHGA^Z\Y@4C:)@L*@=!SWKZR_X9]^&W_0DZ/\
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MXG&GZEXFU^P\1Z/=1V^[^SKJT4>7O!^^I9>?8U],1W"R1HWW=XR%;@],U*6
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MHH _-_0;'X6+^R?XHUO0?&-UK?Q%U?P+<W&MV]SJLD\L\A4&=YX&)",DF5'
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MQ!!K\WA_2Y-<MU"Q:BUG&9XP!@!7QD8[<\4 =.K;E!]13J** "BBB@ HHHH
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M9M?"<T]S>M<1GS;V67EF7' Y]:^E.F*3UXQ42QU:2U?KIJ^FIV4\/3I_"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX689-U,GLT1IY^-'A4?\ODA^D1I69O[2'<[KBDVUYW-\=/#<:_(;J8_[,/\
M]>L:\_:!MER+/2+B4]FD<**+,SEB*<=V>M#-,ED6-2S,%4=6;@5\^:U^T!K+
M*WE_8=+3'WF.YA^=>6^)OC0+[=]OUNYU$_\ /*)CL_PK>GAZE1VC%L\K%9U@
ML*KSJQ7S1]1^(OBQX?\ #NY&O!>7*_\ +&U^<_B>@KR3QI\>M4OK>5;9X]#L
M<<R;LRD?7M^%?.VI_%"YDRMA;);+_??YF_PKD;[5+O4Y#)=3O,W^T>/RKVJ&
M4U):U'RK[V?G6:<?8>BG##1<I=^AWWB#XF)YDGV'==W#'YKJ<D\^O/6N!OM2
MN=3N#-=3-,Y[L>GTJM].:7^=?1X?"4L.O=6O?J?CF9\08W-)7JS]WI%:)?+J
M<CJT9AOI<J<%LC/>J?3Z5WL.EOK$@MX[?[0S?PA<_P#ZJ[SP/\%8YM6AS:OJ
MFH,08[-?F2,^I_\ KUV5LSHX:'O;]NYZ^1Y7BLVDH1A:*WD]O^'. \"_#&XU
MYH[W45>VT[.53'SS>P'8>]?9WP?^!<<<-IJ&LVBVUE" ;73<8SZ,X_I76?#7
MX*VOAGRM1U<1WFJ 91 ,Q0?0=S[UZJOW?6O@\=F%3&3N]$MEV/Z!R7(</EE/
M17D]V]V*J"-0J@*H&  .!4E%%>4?6A1110 4444 >$?M ?#,WD+>)],BS/$N
M+V)!]]/[_P!1W]J^?0<C(Z5]YR1K(I1U#(PP5(R"*^6OC-\+W\'ZHVJ:?&3H
MET^<*/\ CW<_PG_9/:M(OH<E:G]I'F2LRLK(S(ZD,K*<$$="*^G_ (,_%A/&
M%DNDZE($UJW7 9CC[0H_B'OZBOF"IK*]N--O(;NTF:WNH6#QRH<%2*MJYA";
M@[GWC]VCK7E_PG^+EMXZM5LKYDMM:B7YX\X$P_O)_45Z@.*P/0C)25T+1110
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )5&^O[?3[62
MYNIX[>")2SRRL%50.I)/2O/?C=\>O"_P'\.G5/$-WF>0$6FGPD&>Y?T5?3U8
M\"OS&^.G[4'C7X\7TL>H73:3X=#?N-%LW(CQV,A'WV^O%>O@<KK8UW6D>_\
MD:QIN1]K?&+_ (*%>"O LUQIWA6!_%^JQDJ9+=MEHC>\G\7_  '-?('Q"_;8
M^+'Q DE1==7PY8OQ]ET=/+./0R')->$JH48 P*6ON<-E.%PZ^&[[O7_@'5&G
M&);U36-1UV9IM3U*]U&5CDO=7#R$_F:SQ:PC_EDG_?(J6BO8C2@M$:$?D1?\
M\H_^^13[?-I('MWDMW'(:%RA'Y&EHI^SCV$>D^!_VD/B;\.Y$.C>,=0$"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHM6LB.BBBO5+"O0O@+\6+OX*_%+1O$T#L+)9!;ZA"IXEMG(#@_3[P^E>>TC
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M_MT>&/AG\-?AC!XKN_$'C7Q+XF\/_P!K6MSI>CDRWX#$']TI^5N/I@9KK_\
MANSX=7'PS\,>,=+M];UJ3Q)?2:;IN@Z?8M)J,US'GS8_*SP5 R>>XKSGX/\
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M?:SX<M]*M_$/B&U\HBTFOX"T5DQ.,,^TYQVVBOMBH]HW%@!GN<<U)0 4444
M%%%% !1110 4444 )2T44 %%%% !1110 4444 %96L>']+\26HMM6TVSU2US
MN\F]@29,^N&!%:M% %&QT^WTNUCM;*VAL[:,82&WC"(H] H&!5ZBB@ HHHH
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M3:_.ECH]N,9]1&O!;'<BOH/P?X+\+:Y\'_A]'X5\3"#P[:6TZV=QK'R2R()
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MND'M7JNL?M.6'PSU3XT>+?L7B+7DT./19FTF:]4P?Z5%'M6U0C]V?G&[/4T
M?7-%?+WB#]KS7O"^G^%M+U7P#%I'C[Q,;BXL-!U+6X8(8;*( ^?/<,-J$Y V
M8SDU7L_VX+3Q-X+\)S^%O"-UKOC;Q%JMUHT'AM;N-$AN+;/VAWN,%?*7@AP.
M<B@#ZIHKX^UC]I#XS)^T%\.?"\?PT73+#5]-O)K_ $FZU.$R.\3H&E64+PJ
MY _CW>U>V?'?XU#X,Z#HLUMHTFO:YKNIPZ/IFG+.L"27$F2/,E;Y44 $DF@#
MU6BOD6S_ &YKFS\&^(-2\0>!?[*UJQ\2KX1L=.35H9(KW4"NY_W^ L<2@@ES
MGBI/^&[;73?A[XRUC4/"DL_B;PGJ=GINH:)I.HQ7<<QNB!"\%PHVN#GIV/%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC'QKXH^">K:):>!O"?@/Q!?>*--U1[?3=4FNUN+>!LNTTTF26SG % 'J+?\
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M3_%C]K2;XF:7^S]XG^'&L:EHFE:_XV32=5LYHQ',0O$EO*O/0^AKU;4/VWO
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M3*O'H[7!M%A"K.SL0O'TQ]*MQ^*M0L;R&U@GBB%K.EJ=+6++/&$S)(6Z@>E
M'JM5_M$?F>5YB^;C=LR-V/7%</X+US6M2UJ%+^>.:"YLVN_*6'9Y(,F(QGN2
MO6L2S_M2X\12W5G?)]JU34)H5N)( QAMH1@A?K0!ZW17E"^/-45C="[CG&RX
M\VP6'FW6,$(S-UW%@./>E;Q%XKM)I5FU&"4PO:HRK; ;Y9<$QCV []: /5J*
MX#QOXLO=-U2>TM+R.P:WM1/&&B\Q[J1F(6-1Z<<XYY%5/^%A7OVYK5Y(X[O[
M85:W"9,4,<>Z0GZGH: /2J3/IS7 1:IJ]O\ #N]U74[H375S;&2&.&+8(MXP
M@&.2?F6N6T6ZOO#4EU$\J:;</+!92L6:2&(%-YG.[JS#CTH ]IJ-9%;(4@X.
M#@]*\OTOQAJ6H7%I9W&IQ:>F'E2]D@&;Q ^U-JG@9 .?PK.TWQ)K/A^WNM0#
MK<QWL=S?BU:/&SY]J,6Z]>WI0![+17"Z+KVL6OA?5=3U&:WU PJTENMO@GA<
MD,5XZ_I6#9^,M>O&N+>TU.WO99'MH(IQ;XCBED.7'^T%6@#UBF*ZR+N5@R^H
M.17DNH>.M5M]-DBGU*.T9$N9%O3;Y:XV-L1%7&,D]?PK3U19='\'^&M/EN)+
M*TN'CCOKI"044C<03_#N/&>V: /20P;H<TM>.P^))=+C>WT6UM]/-Q=-!]L6
M<M"RH@.Y2_&26Q^!K3;Q1XE6\3?=6Y6WN+>T>.*#(N)&&9"&[ #TH ]/HKRF
MU\;>(;NQU'4UFM5B*F."TP&>.1I L>0.>F<YI;K5M<N)K73[G6O(==7$!NXX
M0@<*FYDQTZ\#UH ]5J-I%5@I8!FZ GDUY7_PGGB!EO\ 4E>U2SA9XOLKX+Q_
M.$5V Y&.2<\5%K>I:FU[#>6NM1W;:98R7)NEMQB1G(54"CCUY]* /7:*XSQ5
MX@N+'^Q;7[7%I<EZ"9KR1-RQ[5!V@'C))XSZ5@KXVU/^TA_IT<GDW+6[V(@P
MS1*N6F8_P^H[4 >F+-&S85U8^@(IS2*K*"P!;H,]:\:TG4KC2=EPLZVCR+%;
M-=SJ66 R%I7;!ZG! %,N?%6HZA_95Y+J\5O<0075S#,T&#.N=D:A.FX\T >U
MT5Y<OCC6)+Z+?-'#/%.D,FEB++NH3=)(3U ],<55N/&6M66GP7%[JD-F+J":
M]1OLP.U%.$B4?Q,V030!ZW29SR.17DS:YJ[7&H7%WJ.Z6+2X%-AY8"O)+C+8
M]LU);>--1L9(]EQ&8X/-BETM(N88XXS^\9NH)8#CWH ]6HK@?"?B#5(]2DM]
M<OH9 \$#C;%L"329(C'KQBN^H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *IWUC;:C:O;WEO%=0/]Z.= Z'Z@\5<HH ACC6-0JJ%51@!
M1@ >E3444 %%%% !1110 4444 5Y(4N(V1U5T8%65AD$'J"*CL[.WTVU2WM8
M(K6WC&$BA0(BCV X%7** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M (6M8F8ED5B<9)4=NE,DLH+A<20QNN[?M901N]?K110 R2RMY54/!$X5\C<@
M.#Z_6G_88?.64Q1F51@2;!N ],T44 5FMK1LYLX3Y_W_ )!\WUXYJVUG$T/D
MF-##C;Y>T;<>F*** $^PP>08?)C\D\&/8-I_"F1V<"QX$,851M"A1C / HHH
M H:YX8L_$5NL-SYB1ABQ$+;=V>N?6K5KI-K#9K;)!&+=46,1E01M'0'/6BB@
M"U]EB^S^1Y:>3C;Y>T;<>F*CCLH8XD58T5%!5550 H/4"BB@!/LL/F)-Y,>]
M$PK;!E1Z ]A2I8P0KA(8T7=OVJ@ W>OUHHH BN-'MKB&XBV"(W"[9)(@%<_B
M*R+?P+I5G:QVZQ,\:72W#!VSYD@& 6]<>GM110!OR(LGWE5MO3<,TGV6%H2I
MB0J5VE=HQM]/I110 V&R@A5=D,:*.BJ@ &>M5_LEIY*Q?9(?*67 CV#:#ZXQ
MUHHH L-9P-,I:&-F5<!B@R!Z?2D^QP?:#-Y,?FE,%]@W$>F?2BB@!;C3X[BW
MDB!,.]-A>+Y6 ]CVJGI.C6NBV,%I:Q[8H244MRW/4Y]3110!=6QMT>0B"+=)
M]]M@RWU]:3[+%RWEKG.[IW'0T44 +):PS21RO#&[Q'*,R@E?H>U#6-NLCR^1
M%O8?,VP9/U-%% #FC1E\LHI7^[CC\JCFT^"XCD66*.17QN#H"&QTSZT44 /D
ML8)&C9H8V,?W-R [?IZ4OV.';CRTQMV8VC[OI]*** "&SAMX?*BBCBC_ +B(
M OY"FQZ?;PJ%2")%4Y 5  #ZT44 -DT^WFV!X(GV9V[D!VYZX]*EDMTFB,4B
MK(A&"K*"#^%%% %-K.T,,$#6L30Y^6,H-J_08JY]EB[1H.=WW1U]:** ($T^
MVCD?;;PJ9#N8J@!8^I]:DDM(7QNAC;:WF#<@/S>OU]Z** &_V?;>9*?L\6Z8
M?O&V#+_7UI8[&"./8L,:IC&U4 &!T%%% !):PWT0\Z&.5<Y"R*& /KS2?98=
MSS>3'YCIAFV#+#T)[BBB@!9+&"1=C0QLK$$JR CCIQ2?8+:1D+6\),/W#L'R
M_3THHH /L</VIIO*C\UEP9-@W$>F?2I)+*"8('AC<)]T,@.WZ>E%% $?V&'>
M93%&7P!NV#.!T&:=]A@621Q#'OD&';8,M]?6BB@ :SB8Y,:$Y!SM'4=#5FBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
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MTHA3L"9K-_6_7J[+O'-_;:S(_-PT?Z:,7)-M-0;Q:](Y%YIY"&.-OQICYL&
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M6FI<(0.LH8+08Q@R X)9MIB [0=W:28C+FMMILFX.RJ52[M62SF14QMS$J[
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M4Z+;TKV5#&P7[6K7][^SHP0OTY8_G&?FYV_:*>W>GNILG_UY@WOCB(O:FBF
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M/S<VB.UTZ>B.>6%HNW8Q0A>XT;,"L]']+-CA!K]5X.X8A"NF^82GW<=/_$+
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M=YPE \^)=>=2((*U&YX=>\5/(C= &PA'-WVXV(A<L/K*3_R67+D![4?0^YS
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MNO6S0$1>O+Q"3%PKN ;:(S\"VS++1F-]^=TD8=T%-!B^'XA,]HB/F+?C<2$
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M=1=U*'X10@@AA*00K@ &ZPW,PUWIJ-.IA1CF%2"$$!_F6>%,X=Z(A&5]9%
M(V'EFOY71RR5,*(A7 N!6GGI.B1;8,)HAIH/RRX5>'KW_G7$^@GEX2:(6%U:
M%LD?R#Y9X%J)[6%-!:LT=2>$U19<'[5^N"@F@PIXJ,_?-AWA$7D:-PQ >,/Q
M07S3;9!.%!CSBQ!"""$D13!.CLZ?PTY"W*_]SLRF[9FR>==NF;PX4QZ9F7/
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M!3H0!4V_?OU,N\/H.AC4T87H%091KK!!!Q<B45$0_>*!MJOP!2!@ %I_G7A
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M'UX**N ]<8%K(UPZPSS28A@H=/%K\HH#\LOF^,-I,^ ](8000DARJ/AUQ!/
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MIO,9Z6O\6F"<6[;L_MHY!!VF]['F%2"TK5CQD[COKS/R++C:#=9O3*WT5FZ
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M\CD2V,+IB"'F$(<061"%O!"%T(6(8N$8G&+A9990K*MDYPAKBY,#@UN;6H=
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M0XG/X!CJ^,J"Q"\AA!!"B Z!3AT].ZR@$+^V[0SAQ;7KP\OK-X9['M\8/O5
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MX8HOU?^+B5A/$88I?7DPW?#  P^,UE?SYLX=8,V5MB[CG%EDW7''#Z+%U%#
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M?WZT3LC[A3\-Z2$\%@,&HIF/<RC(6E_NN]_];LR3#8#9(M3=?OOM\9@RL'*
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M_SQX8N@[96KX7X=/#$=-'YN<$4(((8000@@AA!"B&%U]%9+]$87UO-)3&%D
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MY[-$-B&$$$*(H:1MXM>UO]H:MU/&=H7_>?#$\!]OJ?Z%G^O?,#D<-;W:*4(
M&PT@(GWVLY]-CNJS?OW =2ZRL 7G<>QCS45'GBF+[WC'.Y)0 \':ZR<_^4G<
M9Q .#/3\8._?_NW?:M,M6>N+*9177755<K8<>+$'$$\8I-A@GD$-QU@M&>E!
M%)8R7FA!G#'K&0;!?K!J%G'$:W!_&ZR9X&26=";T6/H8--G].8? 8>?8$I=-
MMT(D\->2EGJ#;R ??CIA.F^&MWCP>6D$98$84E0(2L.]N-X$*Z/1<S2XUNJZ
M"8=#(9:8L 24F7^FQ,\S]676"I2=B2J P)>>HLG VLH@JZX-%N+V][2R\WDC
MK[[.4Q:(8<!SXKS/!\($F#CDGP?'U'-/EHCQZ*./)GOE@7?3V@V> 6UJNMYZ
MO"!H9>(A/NJO;V-%.4"8]FUQ%M1[ZK.)O6EXYO6N[W1LD?FLQ>[3TR'K38_\
M7X=/BMO[%NU1^PN.6(EQC>?%K=G7"R&$$$(,%6T3OYY*.DI_.']"N.:W)H7?
MV*N:E-\[8$)XY/@]P\Q*YPBKL*N>K(ID98..]9HU:Z*0A(B$958:PMC R0:(
M9K7%-?XO,=:# 18P31*1P*Q'@&,X]]QS8[C''GLLWHLM0A># .Z#I<?G/__Y
MN"88TRM_^<M?QLX_?JT*'\,!PHX71$@CF(!DTS7K367Q0HN),V:!!%CG6/R^
M+// NL.39XV$"(&U@,6-LV<'S5HRD7[RX2U0S*HF_<P8U%/?$#;,$JT(#.X8
M *;7ZRJ*B2=IP:K1<S1(K[TCZ<$FY6XB31;DT^+'M:,>^_OS;.I1K\[F0;FE
M_PQQFO0TPT:D!_3I^FV80.3C;F2I2-R^SJ8MX=J);Q=,G!V,T(J8R3M'7H=2
MT!2#@^=+V^.MS?) %.8=*U,]+0MFS94U%3$]'3)O>N3M1T^)0I?_ZXTXID"F
M_^+CK(EM785#"%'!NA!L98LIA.A$VM[;.'!*]F!MUL3&@[AVPUI95U]]==QG
M4%A$S&*PA=45T.&V01/67?PE1V#M+1,#V)\ZM?%?,#&1Q:95[K777G&+ (85
M"%9'L&Y=_U]MLG3\QW_\1]RV&Q-[<%X0P0+#!MU%! 0&X QL61LF;8%DPI#%
M[2V$BI(GR" B>,'3G%G=Y(D,>2 4I<4A''Y>1+(I; SVS)*K&6L4IO90YFF+
MGB(@<J6G319YCD7 DJI>>/+JXV]5R-A___V3O>9(/V_VAQJF-&99^AD\9T0W
M7P[-DK96,WAG$$9]W+@L2R\/UUE8XFY&C!U.K%W@W:%,6Q5\/;QSQ,ES$B,#
MTX!I6[S@:,(W:R/2[H,)MB:\\T-'ELC%'WJAS;1VM%-A,&L#VR(,Q6+W)\\>
M'^Y8M:OE&%9>7&,\\,J.N""^7P>,1?#Y"Y%"""&$$$-%V\0O^Y7OD;6[=ICX
M"Y!/;ZH.XOC5L,PPX&;P ]_ZUK?BUDA; 5D'W<00K+_HF'/NR"./C,=9?/C#
M'QXP^/2"#<=@::"#[SO\;(\XXHC:@L.6)M8%L_N]]:UOC5M+IV%Q(<R-!";V
MF%!E,* !!OJ<(T_^KQ1FB4H,;!G@(OKY06[:0B-MB=0(XD*0L7C8VH"*,JYG
M_9,^SV"KGKC#N:P!NA>%N#]QF@!E@D7>5)XLN ;AQ@34HIC(Y:?,09'G6 2$
M!9YU^ODBI@SE0-4$54L7^<IZCNFZ0]X]]42J>J3C]=!6<)_TH)UCTINV"BM:
MMH990_GKK+Q9S\S7]58@KE;7;1L.[/W-JK>M@AA(?&41^3H=>V[^&T#[9VT.
M[8;_7MI[RG<S2[CE&H1YWGG[1G<$E:Z!2>%LXWX3W2DLLUB+RZ8JXK#DREOL
M_OS73!@0]M_?LE>T!COED5W7;GUV<]^ OAUA$,G^\K<FUZX_>][X<.Q]&Y(0
M0H@1(7DM:2_<<$"(W9+]YLQ+]D0GT3;QZXB]JR;OK"?QNGMZXN+VYDZX?T.<
M\LAZ8$R#+!/3IDV+6V^-=<$%%\3M+;?<$K=O?.,;XS8/.N]WWGEG3; "ID_B
M5P2SZC+++6"0S)I@YL>68W[5A@]\X -Q07P3Q8#[,R!(BQ3M@K2:2.<A?:35
M+),(QP#6Q#K\?;Z ,F;0@Z#C![D,?O"S:YL=F!,70A'WXWJV)F8RZ.*<Q6W.
M!E1F)6+^6)#E60O9-288>6P*)X(% V[B]'FT]#0C$)&V-*3!TDI9,CADWP;Y
MB%P(;6F*/L<B8#F$@&+IP$%6>EN%=/$<;*H> @F#80_6<59O3(CBW;$RP37Z
MJXQI3#BWNI0G,C& IQSL/CC*EV>>KE/\,8?TNU /\DX^_-1:$U*)GW*P])FK
M)[!QSH>%H7Q6@\7>DZQZF\:7":Z>N$49TB8U*SZ*;*S,*5-[[[P(3GODOP'0
MR"*Q'M0+ZD21:?"C@:1((NQSZ+P*\6O_V+/+=$5$*J9!LF^+V]MQVOUFI5\W
M\T?9:YS^\;]NCF$\Q.VOS[M6"#&,) V%;R]\>R*$:(Z++OE8N/&FI<G10*Z\
MZNIP^IE+DJ-BW'??LK#PZ&.3HRK$GXZ'^R+>_3)G=@=P#6%PI,7CSZ7C-G\<
MZ3'LGN8X+B-=E8&5_3@XXKSF'WK"TYOR%SG]X/P)X:^/G)P<"2'*!(-.!OV#
M63=)""'$$).8>O7NK+@=%;<MA%?6; @]KVP.O[:R7#\H"B'*P_HCIH:QE6'7
MN$DAC*DT%6/&5?IZ8Q,!K*0B6/>JU6'RI$EAGVF-EX@1(TMO7U]X_!=/A-<=
M?ECB,[I P%G]0G=RU!H(0$<M7!C./JLYD2L/Q*9++KTL+'_DH<2G*GY]][;;
MPJTW5T4VQ+&++[HP7'C1Q>'^9?>&PU(S:(!XEJ]8$2ZY^*(HD"U:?$(M+$+8
M0P\_/""^LY:<&<-R;N&"!>'XXQ?'^UYU]36UM)#7_>?-B^'*3%O7_+KSF#W"
MFV=6_Z*0!XLO"5]"E!<L7+ (DO EA!#EH_:K9F7 VE7IZ8VAMS>F;;]U"B%&
M ;&M0.RJ;,LL> GA09 QJR.SBD+0\59(9@&%8./]O<43@I#YIZV6TO%Y:RZ.
MO845QT <-]QP8Q2ATF& ..P^MD_Z"9NV[FH&Q*A&8AOBE8E4"%ZLI_K"RA?B
M,<+7!>>?'_<!X0L_X!JNA04+WMCPCW*5D;:*7_R%QW\ZKOKGKZ_\S4G17?^&
MR6'CN_:6\"5$B6&:4-Y"Z4(((4I 9> ZAL%K%+XJAP/_P*(00@Q@#'_D-6DO
MHG".J^Q*-A=E!Y$)*RVS0L*2B6,<%DWGG/N^Z(\HY/VO^%+_^J%G+#DKW++T
MIG@."R8/\=DYKD/0\E/^LKCZRB^'<\XY.UQS]57QNBP++ ]YN.$[WXYAY\\_
M<(# YD%P0B S1UH& _D@3A.UGGEFH*"5]\?F[KCC!V'QXH%&$)2GI:M1^;2+
MMHI?=[VX(USUY-:X?_$A$Z-CC:^_>VY;]&?A>R&$$$((T1QFN8'55YRZ-$Y#
M6"%$/HA?T?(K$;YH,=1JB-' 99?V6VJ9Z&(B#,*5MU RZRK\#:[!^LD$(#]U
MCW.(/'8.$0M1JWOERG@\5!"G"63''G-,6)D3/^E$(#.'N#88F$:)L-<,6+$A
M=-G42$#L\VE"3"PC;5OS"^'K[0]MC%,<;SMJ2CAQ5O_T1Q:]9R%\ID1B&2:$
M$$(((1I#KRY::]"[ZZVN_;7VE0VA9]W&,&?F?J%W>W4ML+Z*?Q^_,5;"U7J"
MR9;KVXTE*8IX'<[S*U>%F3.FATD3)R8^HBQLW;HMK'YY33@PQ_IAM,%[9<)X
MG-Z(&Q_"6(0OUOBJ.$0P.V?ARHK6_"HO([7FETU=-,$*L2J]+I9ATPP1:@ 1
M#+$FZQI_[BO77CM Z"$>6\N+<'YM+;L.?+@T6'8]NGQY3(O?AW2>C*QT<JU?
M\\M(IRL+%K-'://W01R\\DM7U,0^TO)\=W<M;4#<"&86)HLB]V\';6O._N*7
M58NO=\T>-T#X@J4+ID11[)_7[)#UEQ!"""%$04PLBIMDX%I=N+HO#FK'3@QA
M'(M:)V[LE!#&[U'9KVS'L:VXL14WIG(\&$<<15S6M;A:6BK[G>ZZ)E>>3<5E
MG9-KKXOU<5+G/!O>=;;QW4_<N$J;$ 4OA"_:"B]\)>V)$*,%!!DLO1"*LK I
MC7Y:8?H:OQ88YY8MN[]V#JLGIBBRYA5@B;5BQ4_BOK_.R+/@:C>(4Z>=>NHN
M MNB1<=%L<^X:>G-4< #RL!$K7K"%V5+N91-^(*VB5\O;JV*6D=/SUZ$XJ I
MU=;VQR]NCULAA!!""-&8:#65#%SC('9,5?B*?\&MXL9.J@Y^$;S&LZVXF@"6
M.(X'XWQ<]5S6M;BLL)WJQD[JS?27*X<;,[F#G@_O>O+NQS; _K(C#@',+7B/
M,PM,(4836"4Q[0ZA!H>%$WSTO(_4UJ7B+Q4BT!@V58]SX,_Y^&S]+Q-V["\K
MVG6>]YYR2NU^Z07OAPN;U@FD-6OQ?!/I+-TX;Q7'NE_FCQAFEFLFBA&OG3<1
MT8YQQ)ME>5<&VC;M\>C[-H1'U^X,9\X;'RV]/%A[+;QW0]BTLR\N@L]:8$((
M(800HB"5WEWLX57<J^M[PH8-&\*\_>;4_.*4QP3\JC\YBG;P]'//A_UFS@B3
M)T].?$19V+QE:WCAQ1?#P0<>D/B,;GC]:]9<B< U8&MF$=Z_Q&C:8WD9J6F/
M0C1#V\2O/WQL<_CF,]OB/FM[S9K8W[K>\]*.L&9;-5G\)4@AA!!""-$<)FJM
M7=<3>GHVA /FS8FC7Q/ 1#GXU;//A_WVG1&F2/PJ'8A?*U>O#H?,[[<"Z1B2
MH9=9>,7#RC]>'"L[$K_*B\0O44;:)GYAW?7.AS>&IS?EK^F5914FA!!"""&*
M02]OW?J>L![Q:^Z<.)Z5[E4NGGKFN3![UDR)7R4$\:M[U:IPZ$'S$Y\.H](8
MF/@%-2%L% A?(/&KO$C\$F6D;6M^_<9>8\*=Q^P1K;[2L-B]A"\AA!!"B,$1
M![&)LWVV<G)R<@,6MD]<W!="B ZD;99?::YZLOK7'V=,Z J_=\"$N"^$$$((
M(08':W[U;*A:?AGEZ/T)D.57>>EDRZ].$+ED^55>9/DERDAIQ"\AA!!""#'T
M9(E?HCQ(_"HO'3_M<90C\:N\2/P29:1MTQZ!=;\N_+<M8<F*3;F.,$(((800
M0@@AA!!"M$+;Q"];\/XOG]H:;N[>GNM^_.+VY HAA!!"""&$$$(((9JC;>+7
MQ_]S<]V_]&BP!I@00@@AA!!"""&$$*W0-O'KJ8U5X>NHZ6/#CX_=(_2=,C73
M:?%[(8000@@AA!!""-$J;1._]AQ7M>A:,F]\.''6N+@OA!!"""&$$$(((<10
MTC;QZ]CI5<'KG];LB%LAA!!"""&$$$(((8::MHE?U_S6I#CE\>]7[0CO?F1C
MYE]Z_,/'-NNO/0HAA!!"""&$$$*(EFF;^'7T?1O"HVMWQGT$L*R_]/C-9[;I
MKST*(8000@@AA!!"B)9IF_BU84=?LB>$$$(((8000@@AQ/#0U5<AV1]1[GIQ
M1_B/GJKE5STN/F1BLB>$$$(((9KEU?4]H6?#AG# W#F)CR@33SWS7)@]:V:8
M,GERXB/*PN8M6T/WJE7AT(/F)SZB3'2O6ATF3YH4]IDV-?$19:&WKR\\_HLG
MPNL./RSQ$:+]M$W\$D(((800PX_$KW(C\:N\2/PJ-Q*_RHO$+U%&VC;M$?[N
MN6WAJB>WUAS'0@@AA!!"""&$$$(,%6VQ_/K3_]H2OOJK;6'-MEUO/65L5WC7
M['%AZ8(IB<_(L&V;%M870@@A1.>Q<?/FL'G+EC!S^O3$1Y2)U6O6A&E[[QTF
M3IB0^(BRL&W[]O#*JZ^&V?ONF_B(,L&SF5!Y;_:<,K+C1M&8WM 7NE>NDL6Q
M&#03)HQ/]@;/B(M?2U9LBG_)L1%OGCDN_--Q>R1'PPM%L&'3IN1(""&$$*)S
MV+Y]1]BQ8T>8/'E2XB/*Q,:-F\.D21/"V+%C$Q]1%G;N[(W"\9Y[2%PI(TQ+
M'3MFS) .CL40T1?"^@T;PMY[[9EX"-$:>^TQ=)K0B(I?+'+_]H<V)D<A'#1E
M3#AJ>O^'_NE-O>'?U_>&33NK23ISWO@1MP 30@@AA.@DM.97N=&:7^5%:WZ5
M&ZWY55ZTYI<H(R.ZYM??/%M=TXNIC5?^YJ3PJ[?N%<4M<X\<OV=8?L*>X3?V
MJB;KGI=VQ*T00@@AA!!"""&$$*TPHN(7EEW FEX7'S(Q[J=!^+IE8=6TC37!
ML!830@@AA!!"""&$$*(51E3\VK"C.IWQ:#?5,0L$,+/^^H^>G7$KA!!"""&$
M$$(((42SC*CX)8000@@AA!!"""'$2#*BXM?!>U1O]X-5]:<R_F=/;W0P8T)7
MW HAA!!"""&$$$((T2PC*GZ]86IUNN,_K]D1EJS8%/?3L,;7.Q^N_D5(%L;_
MO0,FQ'TAA!!"""&$$$(((9IE1,6O/_OU2>&@*=5;WMR]/73=OBZ\[IZ>FGO-
M/_2$MS^T<<#"^$(((8000@@AA!!"M,J(BE_PF5^?&&:ZJ8PVQ1%GHA<@DOWI
MX9.2(R&$$$(((8000@@AFF?$Q2^F,=Z[:,]PYKSQ T0P S_._>JM>]7^XJ,0
M0@@AA!!"""&$$*W0%G4)46OI@BGAI9/V#O_QEKW"E;\Y*;J^4Z9&/\X)(800
M0@@AA!!""#%8VFY:A1!V\2$3HQ-"""&$$$(((8008BC1O$(AA!!"B ZGKX]_
M!KJ^WM'G=LD#6R&$$$*(!DC\$D(((83H4$ST8I55]NVX)B2-)ERZ+2]Q]=AD
M7P@AA! B#XE?0@@AA!"=2"(.I46OWIUNNV/TN 'I=B(86W,2P8000@B1A<0O
M(8000HA.PT0@+PPA&E4<XE'OCHI?LATM+J:=_<HV]%:/X];R6&'7OR,NA!!"
M""'Q2P@AA!"BHZA9/R%XX:)0U%45D'#;0^C=%L+.K157V;)?9D<:8SHKZ>68
M].\D#XD0%JW DOS&C>5?""&$$")!XI<00@@A1 ?AISI&8:BWJRIX(1HA>.&V
MA+!C<[_;OJF\;F<E?=%5TAP=(A@NR5/-F@W1J^)D_26$$$*(-!*_A!!"""$Z
M!&_U9.)7=<I@5[2:VK%UH.B%J+1CTRAPE70BA-72C?B%%5C,&YFM.LN^K+^$
M$$((X>GJJY#L"R&$$$*(T0P"$#T[MEA#[0AA[2L;0L^K&\,A3TZJAND@-A\W
M-8P9'VJNBY]U,?VJN*Y18@+VU#//A=FS9H8IDR<G/J(L;-ZR-72O6A4./6A^
MXB/*1/>JU6'RI$EAGVE3$Q]1%GHK'Z+'?_%$>-WAAR4^0K0?67X)(8000G08
MM9\V:R)89TX&C&M_5?(7US7#)?G6U$<AA! CR7WW+0NGG[DD.1)E1.*7$$((
M(42'@?C3FPA"M;^,V('8M,>8S^@AX4L((787;KQI:4UP^N433X3]YLS;18#"
MCW- >(Z]0[0J$Q==\K'HFH%\+3SZV.1H\ QU?&5!XI<00@@A1 >!^%.;^I@(
M8*SYU8G4A"]<8O65;(000NQF''C@@>&99YZM*V@M7KPHK'ZA.[I;EMX4SEAR
M5JD$L*NO_')TS7#V64O"\D<>2HX&SU#'5Q8D?@DAA!!"= B(7K4IC\ ^SBRC
M.HPH?)'GZN' O LAA!AU?.9MMX2+7O]WX=8O/)SX%.?99Y\-%U]T8;CDTLL2
MG_H<?_SB<-FE'PM?N?;:Q*<?!#&S#C,K*&]I!ARGK;0X;]>9Q9E-B4R?LWT?
MQY5771T=>$LUNV]6NBQ^@^LM#,[(2D<6/KZBUXP&)'X)(8000G0278D(E(A"
MO7V=.Q'0\FG6;IV;4R&$Z'Q6W/ED6/?2IKC_P,T_C]MFP6H)$(Z*L'#!@F@M
ME@9!#,LP+,2*6D$M6W9_N.#\\^,UB&J?^.2GDC/5<Z>=>FH\A_79HL4GA/N7
MW1N/;[CAQII0YKGJZFMJ86Z]N9J?1NDBWS<MO3F>QY$./X71I_&<<\ZN"6WU
M:.6:,B+Q2P@AA!"BP_ B4-Q').I +)^R^!)"B-'/@G<>$J;N.R7N'W?FX7';
M"E=^Z8HH' V&8X\YINDID8A:6)/!R2>_.XI&!N=,F"-N1*G##CTT'G/NA94O
MQ'W/HD7'19',"V.-TO7H\N71^LVXY.*+HD6<X=-XU,*%X?GN[KA?CU:N*2,2
MOX000@@A.A2SB.I4<<CG2U9?0@@Q^OG,W6>$JW_Z>^'T3QR3^#0/0LW\^0<6
MLE!:OF)%#)L&T0A+)RRMVC75C[6_HK75N>^K66^5(5VC%8E?0@@AA!!"""&$
MZ!B^\/D_#U=\J?["\5A/$88I?7DPW9"%]+&^FC=W[@!KKK1U&>?,(NN..WX0
M+::& J8W>NLM\.GR8)GETX4 .%3I&.U(_!)"""&$$$(((43'P)1"UJ=*@T!E
M"[<S?9 UM6Q*GP=+*PO']$/B(QQ"DOF?M>3,)'05[L=B^YQ#5+-UNEK%[H-C
MFB1DI<O#U$K\+0SK?PTV'9U"5U^%9%\((8000HQBXE\_9+LCA%[<MA!>?G%C
M6+]F4_CUER943W80K[YN:AB_1PAC)X4PKN*ZQE;<N(IC#N0HF0?YU#//A=FS
M9H8IDR<G/J(L;-ZR-72O6A4./6A^XB/*1/>JU6'RI$EAGVE3$Q]1%GK[^L+C
MOW@BO.[PPQ(?(=J/++^$$$(((1+NO__^T-7557-"""&$$&+T(_%+= 3SYLT+
M]]UW7W(T>KCDDDNBZS26+ET:GPF.?2&$&"U\[G.?"T\^^63 ,/Z\\\X+-]UT
M4W)&""&$$$*,5B1^-<FG/O6I ;\(XQ8N7!A_*3:RPIQUUEGA9S_[61(BA"NN
MN*)VCNO3//744V&???:IA>$87G[YY?#1CWZT=HYK?_C#'\9SD#Y_Z*&'#C@_
M6D 0VMV%$\0\RN")U"*&:7\[]JZ(H';FF6?N<MU0"8@77WQQN.JJJT)W=W=8
MLF1)C)OC1A"&L.W "W8XRD>,;F@+K0TUY]MJ2)_'67L+W@K(^WNL/7_[V]^>
M^%3;<+L.1UN<!C\?1E1)/[>T^,2Q/T_X-#P+'\8_.YY7^GD0WI[?P0<?'&Z]
M]=:X?_?==X>CCCHJ[HORHO4[A!!""-$(B5]-\I.?_"39ZV?%BA5A\>+%M<YU
M5A@&UJ>==EIR%,(]]]R3[%6O3PM47_[RE\/:M6N3HQ!6KEP9M^>>>VZX[KKK
M:N>X]IWO?&?MWG3>_7E^O>:\%]Y& PQN$ R_^]WO)CZB$??>>V\4FW"47Q$!
MC#*V:PA_]MEG[R*V-8M=_\8WOC%NVPU"5B-1C[PCV%E9X(XYYIA"92C*S8DG
MGA@M>' WWGAC;*O3 AC^%@9+G[>][6W)F7X..>20V"YG\?&/?SR>]Q"'60_A
MP(LTB"\X?]\L@:P3,)'/YP\!*DNTXMGP/;-R^>(7OQC;)2]><6SGERU;%K]Y
M7B S$<O"4+;IY^,A'7?==5?X\8]_'(^_^M6OQF\T:<8*##%LM%/)2G1"""&$
M$+LK$K]:A XYG6H&-]:I-H'*L#!TSH&P::9/GQZW?__W?Q^W!AUYSC%P\TR;
M-JTV4'OLL<<2W^J]$;@0PTB/#;JPNH&;;[XY;D<#"(7''7=<'+ \\, #@Q9C
M=D<0;1Y\\,'DJ!B(/_RYW#ONN"/Q:8WT>P"(2<3?"!.@1A*$,=XWQ$,/:;GR
MRBN3(]$)(/;2/M9[-XX__OC,MOI#'_I0%%G24'>(,RV8T6YYT83S)N @\' /
M1!;C8Q_[6/1+"W.C'<K'1#[*P 0OQ"7*.LVB18MJ(A1<=MEE<?OHHX_&+1"7
M07B^DR9P4\8(69=??GD\!LH6O$!FX,=S]<^<]'(]]R%>A+I11Z6(K)38QOU.
M%;\0]MA4_NFO&4(((800 Y'X-8)D_?*,P -TP)FR:/M8;C%02\,Y\^_IZ8E;
M1++7OO:UM6.8.K7Z5T_>\Y[WQ&V6-5I9P=H+JQL&((A@66*,GY[FIT8R4,$O
M+9AYZY_T]#;S!T0C<W8^;?V3OM[?*WW.IPU\O&6<5O?LL\\F>_UE8=,C_;1%
MRX,Y*P/"8)4!)YQP0CCVV&/C/EM_/>']]59.5GX>FPIIKNCSLKH I(G]]/.
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M.&[3$*>/%W%HQHP940#CF/3,G#DSAC$A8K3 ( 9KKY-//CD>(X+=<LLM<=]
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MRT$'4NG)=N&2/..D@ DAA.@T[KMO63C]S%W',NWFRJNN#A==4K6R+SL2OX:
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M*U>&^?,/C/MI;KVY7ZA!\+'Q"@+/XL6+:G&<?59U+&7"C[]NT:+C!OSQ+]+
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M(]-\\F'AV9)VZFZ]MH%VS3^G>K^JUTM_T5]J>3_\-[8>_GES3^N0,W"T*2K
M<_&=];SK[-Z&CR--O?<B[SE3EOX9\1T;['?=VC@K+^NPFP,&(/9.\QSR^D0G
M)59P/D_LXS@'/&/:**,5"Y!T_RVO/>;=Y;SEC6=&^L@+_K3YEL^\7[ -RS-Q
M^6<\7-2[7Y'O!>]J$=)]TD;X\O3]RD9UTZ>GU3;?J)=6J\_-],W2::,\+&W<
MBSSG?0?\NT XP_=W+0ZCWKDT1<J*NDM=]FTDQ_1OZGTSB)OWW2SKZGT[3TH$
M"IR]R\W6':"-A*QO]V H^IVA'Y8W#LE+6]Z[U&Q=29,N_WK0;M9[W[FO;P<;
M]?L(B_!%^DD'6+\?[#V"5OM4:?+:-+L_T^W3PNI@[UOO&V 4[5LTB]6G(N->
MTL6[Y857G@%EEM4^--MWJS?^2).NCXWZ\ ;Y]/T'*^,B[42C-J3H-Q]__^Y;
MFBG+>F7&LZ)<+!W^'.]>WO>D45DV8D3%+ZM<J),X! 6O0O+R^7,VM2P-YJP4
M,N'HY/J/8!X\ #Y(9L:89]WC04&U])B9+/'0^?'G2+<-X*G@YH^CT?0O52L0
M-Q]MBS/+])Y[4+DXC_+M?WWC')U>NQ[7J,)#.I_DC9>*N'U<C0:.1CH=- J-
M.KX&Y4XYV+5%GGD:[NT_CM0!7B![F2D3CKF7AW+%T8C8_>N93:.Z4W\)QR_O
M?O#6"/+(?:P^P6#*O%5X]RP/N%:G>V1AC:3/#W4K33H-U!__X2P"]<O>"^JR
M/0O_GN)O9K@\5^Z9!??VC30=T;QV *AO>1^*9DF_B[[^D0[JC.^\%&TCZ\6;
MA[VSZ6NP.$H_UZ+X=-!&<YQ^#_.HEU?JC,4+_IRMC]4HG0P^+/ZL=I.Z8_%D
M6=]D05WR[5G>CR<&Z:9S3%CN9=_&>FT#SXGZ:OZ411;UTD^=HOR*O/\\+^YA
MWUA<WG>&]Y"U* A#V9JU&F7BOW5T?+PE6]YUE /G[#K_+GCJU95ZSSE=YXM^
MUWD6]<J.-)L VXAZ5ER4/4*9/4<<^W2$[3VRMLG.^SY"4?AF^^OSVN-T7: .
MD3ZP09'%@^,X"])L=9BXK/T>+O+NE_>]2&/E0;A&W^BL]X5GE@=IL[!\6ZS^
MU:N;W,/>"XN[E38?[/[I\-R#<Q9?WK<F3:.T<:^\[P#ES'WLGKY>D'>K7UE]
MX;QS6>25E7_/>!;DG^=M?K0C]EP\OMX3ATW-J_?MM#I%?JTLV#93=\BGA1UJ
MBGYG\/?]?TMO7MJRZH>G:%WQY)4_SS6O_$Q , AG<>#(EV\'&_7[")ONX]L]
MTM^MP?2I#.Y3KPWEGMR;?J0Q%/=-UU&>E7T#@#Z/E>500K_.ZD4]T=) ./+U
MU]KMO#$0S\^W=_7Z;KP;5N=(4[KL/92_A>5[4[0/#XQET_62/DRC=H)\<*[>
M-Z#H-Q]_SOO[F+Y3K\Q(HZ6#<[Z/@W^6]F%IP*_1=S:/KO7KU_<E^T((,>S0
MT-+XT; !C1>_>.1UFLH$#3H?&DM['GQXZ%S+Q%@,EDZK2W3L^'7/BUI%:/6Z
M,D-G%U&K2-M'QX\.>:,!WG!!NXWHD]?Y+0IM*+]HFSA &2#L=M)S'6J:J2="
MB*&E:-NG?I]H!_0-,+JP^IG^QK;*4'WSRTBI%KP70G0^WM($QZ\;HZ53SZ\Q
M_ K3"*:>Y"T,+H00@(B.I4#:TBP-X@>_@+9+^!I*_"_:.+X%EW_Z3Y*S0@A1
M+NBS^NE8>:C?)]J!MW;#T:<8K/#5Z<CR2P@AA!!"""&$$$)T+++\$D(((800
M0@@AA! =B\0O(8000@@AA!!""-&Q2/P20@@AA!!"""&$$!V+Q"\AQ/_?WMGM
MS%)48?CS*MR(1W*N@'\8SC4;(1HOP 1_HL9X!R9BQ,1S34#!X!48#2#QYP*(
M44%/] ) MJ?<@.89Y]W[=5E573WSS>QO>K]/4IF9[JKJ5:M6K5I5W3,30@@A
MA!!"""%LEHO=_/K)_M^"^(M/A[]#Y^\YUT(]U$>]6X-_BM*_0)P+_L&)ZUXB
MV,",'6 S2__2=0KNUW4=V=.E]C',]O.(F3&%CA@/]Y-#_>*EP;BH<X(8G;LI
M7(=-GH)9W=T$OW\3QMLY&(WI2QCOEQPCA'"=W%2_?]UDS(<0;@(7N_GUZU^]
M>O7:Z[^\^OT?7M\YTV,6-02*'_[PPU=__\?;F_A[4-KCB_+77OW-U<L_?V'7
MOGIN"2:K8Q<2Q]11@W@68<A_RLT?_H;=[0#[XII*@K^7Y:^-6]#>8X(9[/FF
M!@G(Q5_T8T^\'HKZLN+]*WLEW;2-"_KWVWL[X;WDK/*B(_YZN&>SV+?*N,V@
MYTO;L*+-IQB;Z %;"/^EZAG]G'+Q5/_"W6W6Q^6S7_GRU8LOO+3_]/^H#,G[
M$]F/G6?.#6TX!:<:0Y=*U3/ZN:ESX[$LM>W4X_PZH1WN&RX)=#RKYTN>F^BC
M2_.[-X%J'Y=LZR$\B%SLYM<[[[Q[]<@C']F]9W'))MBAW+GSKZN''_[0_M/E
M\^23G]EM3 AT=>O6!W?OZ[DEGO_A<[MT#-=1AZ#/D5]]?]T0Q#SQQ*?VG^X%
M!UQ323SZZ$>'@>HQ8,_';"R=DO?>NW-UZZ%;^T^GY;GO/7]WXY;%]ZGT?0A_
M_M-?KAY[[&.[]VR6NHVP*?;I3W]R=PYX_\8;O]M_N@?V]O%//+XKPV8^&Z^S
M"]]3+;[#Y?'*+WYVTALW;-[B[T!C4+;.C2,M!.276XM!\F@L,Q\PMF>@+A:8
M(<!-GAN/9:EMIQ[GU\FQ<7D(ET)L/83+XJR;7^R,$P#KSJ\O9/G,)H,?][PD
MH?>\DF<4''L=K3Q<B^OR2AXM/)%5Y?S.".\E9ZV/LBK3.B]<)M7-,<E JG<1
MJ$OGR"OJ-=$%QU2>5S:_GO[\EW;7\G/@LM1K N=U/;U7_MH^RNN<XW6 Y]-Q
M/Z;RM.5K7_W6U9MO_O%_\NH\D,?+\5FH3.M<C[?>^NMN,T+PU%QOXXZ%'@L_
MV4P/M5]RC/2F-I)'\GH?MVQ*YTA>AGIEJR27T^4AG^C9F> 8&S0D\@B5J>6H
M3S+(UM> [0H"C-["P.5V'2&+M[6E/]F0P^>E?L4NV4QN@7YX"D8\]OBC5W?>
MN[/_= _*:S$C>V(S_CKP=K_QF]_NC]ZS#>F,]M,WWF]\EA]V^U/2.8<ZY6MD
M4]2C_I?NI6\EX?Z/)'DHAZ[Q!<JO.I5D]\+/UW-BY&\%,LSZ9;>M43EDZ^G:
MZ;6QIV>O@^,JQSFA:[?.]= X&-UP>,@VP]GH;=DP=J[QPD::C^UC<5V]]9=[
M-RC0&?TB?= 6/KNN^"S=\JIZE%KVPW&]JM]YE1S2Z\@&=)PTZEOJ];S5+_GY
M>DYXGTO>"C*YO#7?R*9ZY7C?T[7#<94GJ1V\UZOJK75X.1]7Y/-V^SF':WD=
MJMO;1)),O*(+[T.O0W("U^S9 .=4A_>UKN_U2W;I6N^]?7P6U*'C2BV]>WF2
M0![/CUQ<M^I$<@&?)3/Y*"]=+)5S.5IR5J0'E7&=<TYRZ'C5AU_#[9KCR.(Q
M#L=Z\E-_G9N XS7O#"JS9">@O"2UI[:3<D)UD*B3-G%,;>-UA.N))*B+I./>
M%^#E>D@>Y?-VNMPDM;4W#H7+I/HXIOQ^#>4C+>F2.JI]D*H-JES5A]!Y$FUW
M'T*J]7E[)(OP<NK'*K^0K.H7KCNJ.X0M<M;-+P6[W/GE#G =9#Q-PCD6N Q@
MOMJHN\L\22%GQ6>]CNZ"40<+3M7!I@:#W.%:;&[P2AX"?!S#%[[XS-URW/7V
M<GSF.'?A',JJ#(GVXF@J.$WE\8T5]*'C?C>=XT\_\]3=<SQQHGJ_^8WOW+V;
M3JJ+<>Y&4!=/E=1-'.IP'<_<N7#9O7W(R**'XUQ+#KA"/M>M^H]KZQA]0=MI
M"VWC22S/*W#:!!U<C_/DY;-/@, YVO[R2Z_LC_1!M[Z0HXU\C4<30YW(T.W;
M;_]M_ZG/2&\M?3CT,?)S'CO0. +&A-I/HOV"?&RZ<)SQHZ]H]OI]9&<"^:B+
M1!Y !LE'HJW>_^^^^\_=\6I_,U"&-GF@4D%NGMS4]75,]'0OL#/Z4<>1'9L;
M+?;)2YD6V&XMSY.7^(T1U(E\=0P? G5YN^D#A^NHKY>N]_P/?G2W?WEE?)(J
M[FO<E[B_9&SRQ(_D8LQJ3,D'DZ@#^8%RZ%-^#MS>>.]CV^V><ZTGC- /&]NJ
M@Z<*W68<CBL?[7._/+*[7KE9>FWLZ5DLS5\^]K'UZB\K^#>W=?J)=LLG,J^Z
M/3"/^P94"YZ"]"=LCX$VR,;47H?%Z7/?_^[NW&A,@S]I*C_7&A^<UZO' >[K
M1C:VIF^I7WG=C\-NX?WU9^^>8ZQ6T,]2'"28ZY2/<20_OF13O7*S]-K(9[VZ
MGL72W,,<QG'W)Y56#$7?^?CE&FQ("MKH\2KG5 ?G*"]&?@!9.5[',6/2;;H7
MY_;&\HP=D[\78Q/+<2,0J!,[HYT]'RU<)\Y2.>"<CX4E1C8GW6$SR-^+$RFC
MN)6$CFJ,P[&>_-1?YR;Z>RF.:D&=*K-D)[VX#UEUC"2;(%5[HDWH6VVK?5;A
MVBI/7I?/97?[1Q<SZP+HC1,?W]4^N-::&!>.U67+/ASR:1X@M?P6_M3;A3Z7
MUH^]L=ZJBW.]. OJG.C]1UTA;)VS?^U1DS@. P?G@]LG>()G_XT1SN$,UD =
M. D%Z0SPUM,7%1R#RX(<7L[EJN# =;V>O$R6G*_@3 63)Y,F,&EYO<C'G74Y
MO^I\9R&X(:!=@\OH=_B1\?93G]N]QYGV)M)=OMN?W7^ZA_<3[V=@4:9) ] #
MNO6G#M2/QSQIH$F"1!VS\CE#O37T(>ACKBE]\LJX 9TC\);N=!S(IW)\/4\;
M(+U^[]G9"%W+^YNV\M5(P>+L4*@7O3/FD,D#+H'<_I05U_/-GI[N'?2AIZ-8
ML#+^#H4@Y9 V:\$RPL<)Z'T-KNEC[Y,JC]O&&KQ?":9T_5:_"/>7C%EL5N4(
M-'U<$HARW!>:+; [U8'-.MXV7JE?=BK0#_;M==0-0N'V4_WRK-UYN5E&;1RQ
M9OZJ_G(6VD[[T"_S:M7O"/)2IK4H<.2+L!'OJPKSO/NS.C_3QD/F2->9[)(T
M\O\^SD8VMJ9O&=O*B]X<;QOS"->KK(F#7'?H5)N8:VS*R\TR:F,/V9S[,6RR
M-?<0(^ 7JIWJ<[4/^L['+]?P\KR7/EA\<UYUU#G&ZZE^P,\YBFFT&=5C9BSW
M^IH^\O*T1[Z86(YY#!1GB9&/=ANIS)1;$Z>-;,[/C>)$_73%C'^=G9L.B:-@
MUDZP0734B_M\7A:S]C3"?4CU@2[?(>L"Z+6?=NFZM9]\KI^)<>%872Z!'2+_
M"&RBI0NWFSH.>F.]5==2G%7G1#ZO:6,(E\[%_N;7+#@Z;5R03KFKS82 L]>U
M<"@M"/HYC[/QW?@1NK.D-)I$+@TF&IR^[K[XY'338+*]:;A=D!3H',(Y[4QR
M*M 8@1S(IH#\NF'AJ("N%YC,0!W82%U,+8$?(%A;*H=<ZAO0^[776P-/BB@H
M8V$J'RH_1AHM>BKX194CZ0XLUR!PUO$1_C3DTH9A#]<E:6DSYMQ<1QM/ ?U$
M($Z?(]\N-9XXZL%"8Z8]WG:WF5."_;%0P-:9RV77]:F'67HVMJ9OD8<\Y*7,
M(9PS#CJ$ZVCCUL#F7OSICW>VR)A;0\^.9]%\PJ8D-X-N[S<PUOAHY]!RIX88
M!'G8P$17=5-'K)5?MJQT:#PQPNLGT1;=A-(QCU>/L:?[&:.?8QZ4OI26='D*
M9M>/L_3BK!:'K$E#N&3.OODEA\*DRDYT;]'&9.3_&D6YM<Z .@Y9+',=?Y(!
M.:AK!CE()@L6T2.82'PWWN]X$G#HMZ>8=/TW>P0.FO+UJ8]9^'K?=6TFN(RT
MO1=$H)_6#W^#-D.J3*XC1W?MM'F"'M#Y,1L!?)W'[QS7=E&__CP D,T_KV6D
M#T GY)$^>94^ZKE9>OW>L[,1ZC.7 3O6#\$OP5CSK_%HG%,O^O:)F+MY&E\.
M<GL=/!:OL3,+U^.Z7&\F4*7/6W:)KVC=]>,N74MV(."@S-H%R@CT[WVR]%42
MOJ[B=UJ]++;B7PM88G27FS'+&-*8K2 'M&RZUJMQ5VV6?E%Y7M&[[%14_8P8
M^>61W?7*C71=Z;41>GH^9OYJ46V=N^O^E(7[2^!)$_6CHZ=[L*7KW*RM\[S'
M#2WP\9)?<X:@+V86"Z)GQ[!D8VOZ5GFQ(P?9-?_WODJZ)@YRW5%&=K-D4[UR
M(UU7>FV$EIZ/G7N .K!MZ5!0AX]?7:/ZD1EZ?F &KL>"O_=4:H\9.Z:/O-]J
MC,W-&'P:^O'Q.O+1(PXMUZ-G<Y69.)$YGPT=]V7UB;G9N>F0. IF[02;&,5]
MC#F@G35&:=G3&MN2_<_ZDQH_C_I^U/Z1KVPQN[8Y1I>])RJQDY8/<WK75(R(
MKD:^TFG5M11G]:AKTA"VRMDWOW 8!,"ZT]>#R0C'25X2CFSMG?E:!VGD? 77
MP1&K#$' S(*8/#@.RG!WNQ6(XHQ4+WG\45;*ZQQH,<Q=#^X(Z!Q)3@T=Z@X?
MJ09Q(ZI^CGDD&AG1+?5PIZ9W9ZCJEH"+"<C;K@D %* HKT,YKJM'EM$#SGL)
M]4%+5P10_KBYMXOK\%DR44\-#-?2TD>%KUURUXWS+"3<KKB3IW.DF3[L]?O(
MSD94&5Q'2]!^OZ:/<_J7X$/GT)/..55NRARRD<0&% '#[?U=;J!=K3MA"IK<
MAN1;T&^%?FL%L^IOUQ_O!?+H^)KQB?Y]3"T]AH^^="W&K[<!6]$86Y(#7\DX
M[.6I8Y:D]O(50HT%%C;N!Y!?.@+\IOQ>#=X9'P2?JAO[K* ??!1YE%IC#UR/
MT//+U>YZY4:Z=D9M'.FY^I39^0L[=]L3Z H_)U] _?*)I#HNT4EK T(;L-[W
M/A][G6ON/M,V;$5E?4YM@9WI6LCD_I3WJH<TDH/KTI9>GI&-K>E;ZI#.*LC
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K(800-DLVOT(((8000@@AA!#"1KFZ^@]H-F:L,\-9C@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M?FCV']K3XM:_\%?A*?$7AJ*QFU5M0MK-%U*-GAQ(Q!)"LI_6O,?B!\8OC_\
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M=#S5GRT4 !5 Z=*DHH I_P!GVWV@W0MHOM!&#-Y8WX],XS4TD,<W#QJXZ_,
M:FHH B:%)%VLBLOH1D4V2WBEC,;Q(Z=-K*"/RJ>B@"O%;Q0QB..-(T7HJJ !
M^%/CC2-=JJJKZ*,"I:* *+:;9R72W3VL+7*CY9FC4N/H<9JTT:2*5958'J",
MU)10!&$55"A0!TQBF+:QA0%CCV]OEJ>B@!&IC444 >8_&+X3>$OB-!I__"1:
M+#J36]TJQ2,[QNBMM#*&1@<$=LXKM_#6AV'A[1;.PTVTBLK*V@2.&"%=JHH'
M  HHKLDW[)%QV-GTI:**XR!:*** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_4a.jpg
<TEXT>
begin 644 image_4a.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !] 6H# 2(  A$! Q$!_\0
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MVEP5Q7E.5^%7U+'13KS@TI?:;MH>P?\ !=X'_A6'@E@#B+6I0['H/W)_^O\
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M6G^+M/\ VH_C##XYM;V/5D\-Q+J/]H*PF\\7F'WEN2V>N>]?MHGW10 M%%%
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M:M6B@!DEO!(A22%6!!!5AP1Z5R;_  &^"[>(#XH_X5+X<_M C_C]_L6#S/\
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MI0 .!117 ?-ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $9&*:8
M\]6_2G44K)NX;D9MQDD-CG.!3E3:<DYIU%%D@$"X/6EHHI@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>recursionlogohorizontalbla.jpg
<TEXT>
begin 644 recursionlogohorizontalbla.jpg
M_]C_X  02D9)1@ ! 0 !( $@  #_X0",17AI9@  34T *@    @ !0$2  ,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[-,3+%X^M*I4>[DV_P ^GEL?1TZ4:<5&"L@HHHKS2PHHHH *\A^,G_("M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9_MN?_GE'_X]_P#%4?VW/_SRC_\ 'O\ XJL:BCZU5[_@@Y4;/]MS_P#/*/\
M\>_^*H_MN?\ YY1_^/?_ !58U%'UJKW_  0<J-C^VI_[B?D?_BJX7QY<)J5A
M#%>1(RK)D ;AS@^C5T5<KXM_X\XO]_\ I7;EN)J.O%-]^B['H93%?6H?/\F>
M:_V9I7_/LO\ WT__ ,51_9FE?\^R_P#?3_\ Q57**^D]M/O^1]SKW*?]F:5_
MS[+_ -]/_P#%4?V9I7_/LO\ WT__ ,55RBCVL^_Y!KW*?]F:5_S[+_WT_P#\
M51_9FE?\^R_]]/\ _%5<HH]M/O\ D&O<I_V9I7_/LO\ WT__ ,51_9FE?\^R
M_P#?3_\ Q57*CEFBMT\R=@J^I_SS356;T7Y 5_[,TK_GV7_OI_\ XJH'DTC2
MI5N(X@DR$,FQW#@CD'AN/K6/>:W+)F.T&Q?[Q^]_]:L,DL2S')-=-*=6,E).
MS+]FI+WC["\!_MK^(O!%[;:5X\MWU739(P1*C9NHAN9>K$"087^(ALD_-VK]
M(/ /Q+\$?$K1UUKP7J$=]#T<*<.A/9U.&4^Q _*OY^/%?^MM/^O?_P!J/57P
MKXO\3>"-8CU[PI>S6%W%TEB;:2/0CHRGN""#W%?TYP-XUYGE4*>'S*]>C9;O
MWXZ=&]_1_>?*9OX?X7&T_;83]W4_\E?JNGJON9_2EC(I.@XQ7YN?!C]N[3=0
M,.A?%^(6<QPHOX%)B8_]-$&2GU&1[**_0_2=8TO7K"/5=%N8KNUG7='+$P=&
M'J""01]*_J[AKC#*L]H^VR^LI=X[27JMU^1^0YKDF,RZI[/%4[=GT?H_Z9LB
MBBBOISR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGD$$9!![$5HLN1@5^VPG&24HNZ/@&FG9CJ***L04444 %%%% !1110 4444
M%%%% !1110 45\#_ /!2K]LK4OV!OV1=?_::TC0(O$T^C7-C;KI\UP;5)!>7
M"0$F14D(VA\_=.<8K^9/_B+5^(?_ $1/3O\ P>2__(E ']LE%?Q-_P#$6K\0
M_P#HB>G?^#R7_P"1*/\ B+5^(?\ T1/3O_!Y+_\ (E ']LE%?Q-_\1:OQ#_Z
M(GIW_@\E_P#D2C_B+5^(?_1$]._\'DO_ ,B4 ?VR45_$W_Q%J_$/_HB>G?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC=V1E32R3R&60Y9J_P!&7]DK_DV'X>_]BYI?_I-'7^<M7^C3^R5_R;#\/?\
ML7-+_P#2:.OT/@WXJWR_4_EKZ4W^ZY;_ (I_E$^AZ***^Z/XV"BBB@ HHHH
M**** "BBB@ HHHH **** /PT_P"#C/\ Y11>./\ L(Z)_P"E\-?YM5?Z2O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?@S_P<+_L6^,_VM_V&6\1?#"S
MDU'Q+\-[_P#M^&RA4O-=V7EM'=Q1J.KJA68 99O**J"S 5_G"U_LP5_/;^W1
M_P &Z?[(7[7'C2_^*WPTU&[^%OBG5'>:]?38$NM,N9Y#EIGLF:/;(QY;R9HE
M8Y8J6)8@'^=C7WI_P35_8O\ %_[=W[7OA/X(Z%:/+H_VN*^\0W0!\NUTBW=6
MN'9L$!G7]U$#]Z5U'0DC^D?P1_P:6:?!XA6?XD?&V2ZTJ.09ATS0Q!<31YYQ
M++=RK$V/^F<@_+G^EO\ 8P_80_9J_8'^&Y^&O[.FA?V?'=;)-0U&Y;S]0U&6
M,$"2YFP-Q&3M10L:;CL1<F@#[*HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /__7[#Q5_P C1J?_ %]3?^AFN?KH/%7_
M "-&I_\ 7U-_Z&:Y^LS^(ZOQOU9<)\U!+W'#?7L>G?ZGFHZ9%+Y;9_A88/T_
M2IG0HVTU\%GF!]A7YXKW9:_/JC2#NAE%%%>(: X60?O!D]CWJO) R@NGS*._
MH,]ZL4JLRD,IP1R"*YZN&A/79EQJ-&=15]HXI.VT^HZ=^WY=/R-5)(FC^\.#
MT/:O-JT)4]]C>,D]CV7]G_\ Y*=9_P#7.;_T U^@]?GQ^S__ ,E.L_\ KG-_
MZ :_0>OQ_CE7S"*7\J_-G[5P#_R+I?XG^2"K=A87^J7D6FZ7!)<W$[!(XHE+
MN['H%4 DD^@%?4OP9_9"^)/Q3:'5M3C.B:.^&^T7"'S9%/\ SSBX)![,VU<<
M@GI7ZO\ PG^ /PU^#MGL\+60:\9=LMY-B2XD]?FP-H/]U J^V:]OA7PPS/-G
M&M67LJ+ZM:M>2T^]Z'Z+0P4YZRT1^?GP8_81\1>(/*USXM2MIEH<,+*$@W#C
M_;;E8QTX&YNH.TU^GO@KX?\ @[X=Z.FA>#+"*QMEZB,<L>FYF.69O=B37:'I
MZXH5LC!K^D.&^#<LR6G;"4_?ZS>LG\^GHCUJ5"%->ZA]%%%?5FH4444 1$=P
M:!C/%>0?%/XX_#SX0:;]N\7WRI/(NZ&UCPT\N/[J9Z?[1POO7P1%^WEXRU3Q
M5)J&F:5;Q:/"506LC$S.K9^8RC@-QP I R<AN#7Q7$GB!DF1OEQU;72ZBKM+
MN[;+\?(VPE"6)Q$<+1UG+9?(_5;((R:>,D5X=\+_ (]^ /BK$(]$N?L]\!E[
M.?"2C'7 SAA[J3[XZ5[> .<<YKZ+*LXP69X>.*P%:-2G+9Q=_EY/R'B<-6P]
M1TJT'&2Z,DHHHKTS A)/ [>M<=XT\"^$/B'H,WA;QMIT&IV%P,/!<('0^AP>
MA'8CD=J[ @9!')%/.>/6HJ4XU(N$U=/HRZ=2=.2G!M26J:T:?D?AC^TA_P $
MI[NU^T>*?V=+KSDY<Z/>/\P]H9F//LLG_??:OQP\4>%/$O@G6YO#7B^PGTV_
MMFVRP7$9CD4_1@.#V/0]J_M="D\'I7A?QH_9V^$OQ\T7^Q_B1I45V4!$-PHV
M7$)/=)!\PYYQR#W!K\PXB\-,+BKULO?LY_R_9?ZKY:'[-PEXQ8W!<N'S5.K3
M_F^VO7I+YZ^9_'O17Z6_M'_\$TOBK\)1/XD^&>_Q3H<8+%8TQ>Q*/[T:_P"L
M _O1\GJ5 K\U98I8)6AF4HZ$JRL,$$=017XIFF2XS+JGLL73<7^#]'LS^CLC
MXBR_-J/M\!64EU[KR:>J9XK\5O\ D,V7_7F/_1LE>75ZA\5?^0S9?]>8_P#1
MLE>4W%S;VD)N;IQ&@XW-TS@G'UX.!U-71BY1BHJ[/U'+/]WA_74FK.U'5+'2
MH]]X^"1D*.68<]!^!YZ5QNJ^,W8F'25VCD>8PR3TZ#MWZYX/8UPTDLDTAEF8
MNS')).237N8;*6_>JNWD>O3P[>LM#I-5\57^H PP?N(CV4_,>.Y_H/7G-<O1
M17M4Z<8+E@K([(P459!112@%B%49)K097N[@6L#3?Q#A?K^(/U_2N/)+')Y)
MJ_J-W]IFVJ?D3A>N#ZGGU_#C%9]=M./*K'3"-D%?Z-/[)7_)L/P]_P"Q<TO_
M -)HZ_SEJ_T:?V2O^38?A[_V+FE_^DT=?=<&_%6^7ZG\I_2F_P!URW_%/\HG
MT/1117W)_&P4444 %%%% !1110 4444 %%%% !1110!^&G_!QG_RBB\<?]A'
M1/\ TOAK_-JK_25_X.,_^447CC_L(Z)_Z7PU_FU4 %?T8_\ !KY_RDFOO^Q,
MU3_T?:5_.=7]&/\ P:^?\I)K[_L3-4_]'VE '^A?1110 4444 %%%% !1110
M 4444 %>4_&GX-?#G]H7X4Z_\%/BWIL>K^'/$EF]E?6LHX9'Z,IZK(C /&X^
M9'564@@&O5J* /\ )?\ V\?V0?&O["W[4WBG]G#QFSW T>X\S3KUEVB^TZ?Y
M[:X !(!>,@.H)V2!DSE37Q_7]NO_  =8?LPV6M?"[X??M>Z-;@7VAWK^&=3D
M5?F>SO%>XMBYZ[8IDE4>\]?Q%4 %?Z87_!!G]K*Y_:O_ ."=GA63Q#<_:/$/
M@-F\*ZDQ/SN+!4-K(1U.ZU>(,Q^](K^]?YGM?UF?\&H?QNET3X\_$_\ 9XNY
M#Y'B'1+;7;=6/ FTN;R'"_[3I=@GU$?M0!_<I1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZG\H?2F_W7+?\4_RB?0]%%%?<G\;!1110 4444 %%%% !1110 4444 %%%%
M'X:?\'&?_**+QQ_V$=$_]+X:_P VJO\ 25_X.,_^447CC_L(Z)_Z7PU_FU4
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M!_3_ $5_(+<_\':/PV6YD%E\%-3DA#$(SZW$C%<\$J+5@"1U )QZFNF\,_\
M!V-\ [MP/&7PC\06"[F!-EJ%M=D+C@X=;?DMP1G@<Y/2@#^M2BOP)^%?_!R=
M_P $O_B-,EMXDUG7O!+R-M']N:2[+D\#+6#7B@'U) '<BOU]^"/[3W[.O[26
ME'6?@#XXT3QA B!Y1I5[%<R0@X_UL:,7B/(X=5//2@#WFBBB@ HHHH ****
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MJ*^./@%_P4&_8F_:BE@L?@1\3= \07UP!Y>GI=K!?L#_ -.D_EW'_D.OL>@
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M110 5DZMJVE>'],N-9URYBLK*TC::>XG<1Q11H,LSNQ"JJ@9))  KPK]I_\
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MRO"?[$]I?_LZ_LV3V^N?%F:/9=7# 36F@)(IP\@^[)=8(,<)RJY#2\81_P"
MCX@_$+QS\6/&NI_$CXEZM=:[KVLSM<WM_>R&:>>5NK,S$D\8 '0  #  % '[
M(_MI?\%_?V]?VLKR[T3PAK3?##PG,&1-+\.2M%<O&W:>^^6>1L9#>7Y,;#K'
M7XD7U_?:K>RZEJDTES<SN9)996+N[L<EF8Y))/4FJE% !1110!^LO_!##_E*
M[\'/^PC>_P#I!<U_I]U_F"?\$,/^4KOP<_["-[_Z07-?Z?= !1110 5^7/\
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M_8;T>/QMJL):)O$>IAX=)B<<$P0C9-<X/1B8DSRID4U_-I_P4D_X*W?M+?\
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MO-#T77W^&_A"<LJ:/X;E>WE:(]KB]&VXE)'#A3'$W_/,5^2?Q1^*?Q%^-?Q
MU7XJ?%C6;KQ!XBUN=KB]O[QS)-+(WJ3P%4 *JKA54!5   K@: )9[B:YF>YN
M7:221BS,QRS,>223U)J*BB@ HHHH *[;X>?$KXB?"7Q7;>.OA7KVH>&]:LSF
M"_TRYDM+F/H?EDB96'3D9YKB:* /ZL?^"?\ _P '-OQF^&^H6GP__;MLCXVT
M!V6,>(;"*.#5K52<;IHD"0W**,=!'+C)+2' K^TOX&_'KX/?M,?#/3_B_P#
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M_2^&O\VJ@ K^C'_@U\_Y237W_8F:I_Z/M*_G.K^C'_@U\_Y237W_ &)FJ?\
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M!U_?Y_P:J?\ */;QE_V434?_ $VZ90!_3)1110 4444 %%%% !1110 4444
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MBN\_;=^.NG)J'AWPC??8_#FGW"!H;O58@KO<R*PPZ6P9?+&"#,<YS%@_W;T
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M_@!_;_\ ^"$/[1'[/_[7^@_!K]F?2K[QEX4^(=TZ>&KU@"]LR#?-!?2 !(S
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MM+X.?L%_ +5?CW\9KDBVM?W%A81,/M.HWS@F*VA!_B;!+,?E1 7;@&O\Q_\
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M4 %?87['W[!O[4_[=?C-_!O[-WA:?6!;,HOM1D(@TZQ#<@SW+X120"0@)D<
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M&W_(KG_C?Y1'4445F?H)YW\6_P#DE_B'_L&W7_HMJ_B#K^WSXM_\DO\ $/\
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MG^#,?D=3#J&5I1EU3TEZN^K^3'T445Q'VP4444T*6S/[^?\ @F)_R83\,_\
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M@#_7%_X;5_8W_P"BM^#/_!]8_P#QZC_AM7]C?_HK?@S_ ,'UC_\ 'J_R.J*
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M&WP%^&VC_"#X0Z/;Z#X;T&W6VL;&V7"1HO)))R6=B2SNQ+.Q+,2Q)KTVBB@
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M2.OX /\ @V'_ &L[CX2?MC:K^S-KMSLT7XGV#?9D<X5-6TQ7FB()X'F0>>A
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M_P#G^\&?^#2?_P"1*/\ B%\_X*3_ //]X,_\&D__ ,B4 ?SFT5_1E_Q"^?\
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MOO\ HM/AW_O[)_\ &Z /TSHK\S/^'R?_  2^_P"BT^'?^_LG_P ;H_X?)_\
M!+[_ *+3X=_[^R?_ !N@#],Z*_,S_A\G_P $OO\ HM/AW_O[)_\ &Z/^'R?_
M  2^_P"BT^'?^_LG_P ;H _3.BOS,_X?)_\ !+[_ *+3X=_[^R?_ !NC_A\G
M_P $OO\ HM/AW_O[)_\ &Z /T;UO1M*\1:/>>'=>@2ZL;^&2WN()!N26*52K
MHP[AE)!'I7^2'^UY\!K[]E[]J'Q]^SY?,TG_  B6N7FG0RN,-+;1R'R)<?\
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M]+_]$7=?YZ% !7]_G_!JI_RCV\9?]E$U'_TVZ97\ =?W^?\ !JI_RCV\9?\
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M:_\ !,S3?&[P[+KQYKNIZP[,/G,<$@L(QZ[<6I91_M$CK0!_0)1110 4444
M%%%% !1110 4444 %8^MZ+I'B31KOP[KUM'>6%_#);7-O,H:.6&52KHRG@JR
MD@@]0:V** /\E/\ ;M_9KO?V0/VOOB#^SE="0P>&-7FAL7E&'EL)L36DC9[O
M;R1L>O)ZFODNOZ?/^#J#X,V_@_\ ;0\'?&:PB"0^-?#2PSD=7N]*F:-V/_;&
M6!?^ U_,'0![#^SW\8==_9[^.O@[XY^&2WV[PCK-EJT2J<;S:2K(4/JKA2K
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M#&D.\+')C9K6(E2>Y4\5[S65HVD6&@Z3:Z%I2"*ULH4@A0=%CC4*H_  5JT
M%?QY_P#!VOX@-MX-^!WA7=(!>WOB"[VC_5G[-'9)D\_>'G?+QT)_'^PROXW?
M^#MW3;N73/@)K"8\F"7Q/"YSSNE&FLO'TC:@#^,&BBB@#_3"_P"#?OPPOAG_
M (),_"W<NV;43K%[+@Y!,NIW00_]^PF1ZU^SU?D-_P $'-4MM7_X),_!^[M=
MP5+34X#N&#N@U.[C;\-RG'M7Z\T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!_.=_P=!_\HV;'_L<]+_\ 1%W7^>A7^A?_ ,'0?_*-FQ_['/2_
M_1%W7^>A0 5_?Y_P:J?\H]O&7_91-1_]-NF5_ '7]_G_  :J?\H]O&7_ &43
M4?\ TVZ90!_3)1110 4444 %%%% !1110 4444 ?Y''[:G_)Y'Q:_P"QSU[_
M -+IJ^9J^F?VU/\ D\CXM?\ 8YZ]_P"ETU?,U 'W]_P2H_Y23_ [_L<](_\
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M>Y8@5_K[?!+X:Z?\&/@SX1^#^E%6M?">BV&C0E1A3'80) N!V&$% 'J5%%%
M!1110!_D"_M'?\G"^//^QBU3_P!*9*\9KV;]H[_DX7QY_P!C%JG_ *4R5XS0
M!^LO_!##_E*[\'/^PC>_^D%S7^GW7^8)_P $,/\ E*[\'/\ L(WO_I!<U_I]
MT %%%% !1110 4444 %%%% !7\9__!W)_P V^_\ <U_^XJO[,*_C/_X.Y/\
MFWW_ +FO_P!Q5 '\9]%%% '^F1_P;Z?\HAOA'_W'_P#T]7]?LQ7XS_\ !OI_
MRB&^$?\ W'__ $]7]?LQ0!__U_5_%/\ R,^I?]?4W_H9K K?\4_\C/J7_7U-
M_P"AFL"O['I? O0_SCK?Q)>K"BBBF9GL'P\UXS1'1+ILLGS1$]U[C\/\]*]0
MKY:L;R?3[N.]MSAXF#"OI32]2M]5T^/4(#\KC)SV(ZC\*XZ\+.Z/6P=;FCR/
M=&C52^O[+3;=KS4)5AB3J[G %>6^,?B]H7A[=9:7B^NU."%/[M2#SEO7V%?+
M_B+Q7KOBJY^TZS.9 /NH.$7Z+T_'K64:;9[%+"2EK+1'M/C'XW-(&L?!Z[0>
M#<2#G_@*GI]3^5?/MY>W>H7+7E]*TTKG+.YR3^)JK16\8I;'I4Z48*T4</\
M$8$^#;T#_IG_ .AK7SUI<XGMS;-]^+++[KW'X=>G3/I7T3\1/^1,OOHG_H:U
M\L0S26\JS1'#*<CC(_(]:FI&Z/MN&:[I4VUW_0^ZOV6/VY_VC?V/];%]\(];
M8:9(X>YT>\S/I]QZ[HB1L8_WXRC^^.*_JF_8X_X+"?LY_M-+:^$?'4Z>!?%\
MNV,6>H2C['<R' _T>Y.U26/ CDV.2<+NZU_$T'B=1+ ?E<9 SDCV/3D?09Z]
M**^,SSA' YBG*4>6I_,M_GT?S/UC+<[Q&&2Y7S0[/;Y=C_3;#YYS1GCKUK^'
M7]C;_@K7^TG^RG]D\)ZY<'QKX/AVI_9>I2GSK>,<8M;G#/&!QA&#Q@#A5)S7
M]5_[)O\ P4 _9K_;%TU%^&.M"WUQ8]\^B:AB#4(L#+$)DB5!W>)G4<9(/%?C
MF=\)X[+6Y5(\U/\ F6WSZK\O,^[R_.L/BK1B[2[/].Y]P4445\R>N%%%% 'C
MWQF^!OPB_:%\#7/PW^-/A^S\1Z-=?>M[N/=M;! >-QAXI "=LD;*Z]B*_ C7
M/^#<7X/W'Q9-]X9\<:E8^ KF5+B?2VB274(VCW#R8;D_)Y;!SAWB9TV@'S"Q
M9?Z5!D'%(O< UZ>"SG&82$J5"HU&6ZZ>MG>S\]R:,8TL1#%TU:I&]I=5=-?J
M?._[/'[+/P&_93\'+X'^!/AVUT*S;:9Y(EWW%RZ]'GF8F25N3@NQQG P.*^A
M^0U/51UH=<C KSYU)5).<W=ON;5:LZDG.I)N3W;U'T4#CBBH,R($!:4+CD&@
M[L>E?*W[2_[97[/W[)GAXZ[\8M<BM+B12UMI\.);ZYQQ^ZA!W$9X+G:@[L*T
MI4IU)*%-7;Z(VP^&JUZBIT8N4GLDKL^J"Q'7@>]?FC^V%_P5)_9K_9(6Y\.W
M%Y_PE/BV(%1HVFR*SQN. +B;E(.>JG=( <B,BOY\?VQO^"RW[0'[0GVKP?\
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M HHHH **** "BBB@ HHHH _#3_@XS_Y11>./^PCHG_I?#7^;57^DK_P<9_\
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M(_MD_![3OC?\ =:CUG0]0&UL?+/:W  +V]Q'DF*:/(W*>Q#*2I5B ?1=%%%
M!1110!^6?_!:CX7S?%S_ ()=?&/PS;IYDMEHHUE,+N9?['GBOF(]/D@8$CL3
M]*_RZZ_V._%_A;1?'/A/5/!/B6(7&G:Q:3V-U$>CP7"&-U_%6(K_ "'_ (]_
M!_Q'^S]\;O%OP.\7KC4_".KWFDW!Q@.]I*T>]>ORN%W*<D%2".* /)*_IJ_X
M-<?VB+;X<?MI^)?@'JTXAM?B1H9-LI./,U'1RT\:X[_Z.]T?7CW-?S*UZO\
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MMH82/+2C;SZOU?\ 2/VK)N'\#EE/DPM.SZO>3]7^FP4456O;R/3[-[V4;@G
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MYC4;8[:_D8C9*O"QW#?+(.)"'&Z3^P)'5U#J001D$="*_P :.OW[_P"":_\
MP7\_:3_8GM+#X4_%Z.3XC_#FV"Q0VMU+MU/3HA@ 6ERV=T:CI!*"O "-&,Y
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M3X :1^S]\%K8I8V.9[N]E5?M.H7L@ EN9V4 -(^T =E151?E4"OK6@ HHHH
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M_D"T %?T8_\ !KY_RDFOO^Q,U3_T?:5_.=7]&/\ P:^?\I)K[_L3-4_]'VE
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MLO\ P0P_Y2N_!S_L(WO_ *07-?Z?=?Y@G_!##_E*[\'/^PC>_P#I!<U_I]T
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M^T?A#_P49_;O^ ]K%IOPH^+?BC2K&#'EV7]HRSV:8_NV\S20CWPG(X-?%U%
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M!O#MEX0\%Z=;:3I.FPI;VEE9Q+!;P1(,*D<: *J@<   "NCH **** "BBB@
MHHHH _#C_@L[_P $C/#W_!1;X91^._AFEMIGQ9\,0,-,NY?W<>I6PRQL;A^
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M5'_*2?X'?]CGI'_H]:_U8J "BBB@ HHHH *_RG?^"J__ "DG^./_ &.>K_\
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M;O["G_!/W]HC_@H-\68OAC\#-,)M8&5M5UJZ#+I^FP-_'-( <L>=D2Y=ST&
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M5^='[67_  34_9\_:F%QXAFM?^$:\52 D:O8( 97/>XBX6;W)VR?[>*_1G)
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MCK-_+HO-V7S/P*_9<_8E_:+_ &O_ !"-(^#>A236,;A+K5;K,-A;>N^4@Y8
MYV1AW(Y"XK^KK]BW_@C5^SU^S.]IXS^(R)XY\71[9%N;V("SM9 <@V]N=RAE
M.,2.7?(RNS)%?K1X0\&>%/ 7AVT\)^"-.MM*TVRC$5O:VL:Q0QHO1550 !]!
M73C(.T]Z^-Q^>UL1>,/=CV6_WG\7<>>.&=\0.>&P[^KX9Z<L7[TE_>EHWZ*R
M[WW%CBCA4)$H4#T&*DHHKPS\5"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#Y _;C_8[\#_MW_LXZM^S3\1-3O]'TK6)[2>6ZTWRQ<*UG,DRA?-1TP60
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M$ /^"LOBF48^%9TZ+<4:6^U?380I S]W[49"#G@A",]^#7^F910!_!'\(?\
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MTJC\2*^J/A?_ ,&R_P#P4K\<SQ_\)M#X:\%0D@R'4]4%S(H/7:MBER&8>A8
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M/#EWX1\<Z7::SI-_&8KFROX$N;>:-NJR1R!D93W!!%=/10!_/]^T]_P;@_\
M!/'X]W-QKOPZL]0^&.KS$N6T"4-8LYSRUI.'15_V8&A''UK\//C+_P &J'[6
M/AF::Y^!WQ \-^++1"2D>I)/I-TR]@%5;J+/KF517]XE% '^:#XO_P"#?/\
MX*P^%9I#;_#./5[>,X\_3]8TZ0-\Q PCW*2^_P#J^ ><'('!?\.,?^"KO_1'
M-1_\#;#_ .2:_P!/NB@#_-1\(?\ !O'_ ,%8/%,B&_\ AW;:)#(H82ZAK.G
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M!TK\"?CE_P &G>KI<2WW[-7Q9AEB8GRK'Q-8M&R#MNN[4N&S[6JX]^W]HE%
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M>:^?JT)TW[VQ_1F2\2X+,8_N96GUB]'_ ,%>8RBBBL3WS>N?^/*R_P"N+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_9-^V/\ \$8/"'CG1M7\3_LJ30^']8NH) =&NW8:=,[ C]U(%>2 \G"X:,G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]?^_BBBB@ HHHH
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MRAQQ7]'O[$7_  1R_9B_9!%IXRURW_X3?QM;[9/[6U*-?*MI5P<VEL2R1$$
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
